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Ionotropic glutamate receptors are important excitatory neurotransmitter
receptors in the mammalian central nervous system that have been implicated in a
number of neuropathologies such as epilepsy, ischemia, and amyotrophic lateral
sclerosis. Glutamate binding to an extracellular ligand binding domain initiates a
series of structural changes that leads to the formation of a cation selective
transmembrane channel, which consequently closes due to desensitization of the
receptor. The crystal structures of the AMPA subtype of the glutamate receptor
have been particularly useful in providing initial insight into the conformational
changes in the ligand binding domain; however, these structures are limited by
crystallographic constraint. To gain a clear picture of how agonist binding is coupled
to channel activation and desensitization, it is essential to study changes in the
ligand binding domain in a dynamic, physiological state.

In this dissertation, a

technique called Luminescence Resonance Energy Transfer was used to determine
the conformational changes associated with activation and desensitization in a
functional AMPA receptor (∆N*-AMPA) that contains the ligand binding domain and
transmembrane segments; ∆N*-AMPA has been modified such that fluorophores
can be introduced at specific sites to serve as a readout of cleft closure or to
establish intersubunit distances. Previous structural studies of cleft closure of the
v

isolated ligand binding domain in conjunction with functional studies of the full
receptor suggest that extent of cleft closure correlates with extent of activation.
Here, LRET has been used to show that a similar relationship between cleft closure
and activation is observed in the “full length” receptor showing that the isolated
ligand binding domain is a good model of the domain in the full length receptor for
changes within a subunit.

Similar LRET investigations were used to study

intersubunit distances specifically to probe conformational changes between
subunits within a dimer in the tetrameric receptor. These studies show that the
dimer interface is coupled in the open state, and decoupled in the desensitized
state, similar to the isolated ligand binding domain crystal structure studies.
However, we show that the apo state dimer interface is not pre-formed as in the
crystal structure, hence suggesting a mechanism for functional transitions within the
receptor based on LRET distances obtained.
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Chapter 1—Introduction to the Allosteric Behavior of AMPA Receptors
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I. Ion channels
Ion channels are membrane proteins and function as a gateway for small,
charged molecules called ions to pass across the cell membrane. Ion transport is
essential for various physiological processes by controlling cell volume, allowing
nutrients to enter the cell, and by generating electrical current. These proteins
contain structural elements that are essential for their function. Ion channels are
highly discriminatory for ions such as Na+, K+, Ca2+, or Cl- by way of a channel pore
that serves as a selectivity filter. The ion channel gate opens and closes to control
the flow of ions [1, 2]. As shown in Figure 1, ion channel gating can be regulated by
an outside force such as membrane voltage, ligand binding, second-messenger
binding, or mechanical force thus defining the different types of ion channels [1].
How an outside force causes a conformational change thus triggering a functional
consequence is an essential question in ion channel studies.

The detailed

relationship between the structure and function of ion channels had remained
unclear until 1998; Roderick Mackinnon solved the first structure for an ion channel
[3]. The voltage-gated K+ channel structure revealed how the intricate pore confers
its selectivity. Now with a multitude of ion channel structures available, insight into
structure-function relationships has emerged. However, in spite of these detailed
structures, questions still remain unanswered regarding membrane proteins in a
physiologically relevant environment relating to protein dynamics, structural
investigations of a functional ion channel, the role of ion channel regulatory
proteins/modulators, and oligomerization, for example. In this dissertation, I used a
molecular ruler (LRET, see Chapters 3-5) to determine structural changes due to

2

Figure 1 Various types of ion channels. Voltage-gated ion channels respond to
membrane voltage changes and open the gate (red). Ligand-gated ion channels
respond to an extracellular ligand binding thus opening the gate.

Second

messenger-gated ion channels respond to intracellular second messengers such as
Ca2+ to open the gate. Mechanical-force gated ion channels open when an outside
force is applied [1].

3

4

ligand binding in a functional ligand-gated receptor that ultimately lead to the gating
of the ion channel.
II. Ligand Gated Ion Channel Allostery
Two allosteric models, originally developed in the 1960s to describe enzyme
regulation, have been proposed: the Monod, Wyman and Changeux model (MWC
model) and the Koshland, Nemethy, and Filmer model (KNF model) [4, 5]. The two
models were based on the idea of concerted as opposed to sequential events of
allosteric proteins, respectively. These distinct models have been used to explain
how conformational changes coupled to ligand binding and subunit interactions can
lead to functional behavior of a protein [6], hence the molecular basis of allosterism.
In the MWC model as seen in Figure 2, allosteric proteins are oligomers of
identical subunits and have at least one axis of rotational symmetry. For each
subunit of the oligomer, there is only one binding site for the ligand (S). The idea of
the equilibrium between two conformational states was introduced, where the
discrete states are interconvertible (T↔R) [4, 6, 7]. The states, named T for tense
and R for relaxed, are in equilibrium at any homotrophic ligated state due to a
concerted transition of the protomers from one structure to the other, while still
required to conserve their molecular symmetry; either squares or circles as in
Figure 2. Here, the conformation of a single protomer is restricted by its association
with the other protomers [4]. Ligand binding preferentially stabilizes the state in
which the highest affinity for that ligand occurs. For example, the ligand binds to
molecules in the T state with low affinity and R state with high affinity, so that the

5

Figure 2 Two models of allostery shown, the MWC (concerted) model and the KNF
(sequential) model. Each subunit has two tertiary conformations as shown by
squares (low affinity) and circles (high affinity) caused by ligand (S) binding. Global
conformation states are shown by T and R [6].

6
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equilibrium is shifted toward the relaxed, high-affinity state. In the unligated state,
the two states are thought to be in equilibrium. The modulation of the equilibrium by
ligand binding is adequate in producing cooperative ligand binding [4, 6]. In the
MWC model, several identical subunits are assembled into a cooperative and
symmetrical quaternary structure. Conformational changes are thought to affect
only the quaternary interactions between subunits as opposed to tertiary folding in
each subunit [4, 6, 7]. There are no intermediate conformations in this model, and it
cannot explain negative binding cooperativity, meaning that ligand binding does not
promote subsequent binding [6].
In contrast, as seen in Figure 2 [6], the KNF model does not require
equilibrium of quaternary structure; it describes how individual subunits (circles or
squares) can switch states upon ligand binding. The transition from T state to R
state occurs sequentially through intermediate states induced by ligand binding to
individual subunits; this also influences neighboring subunits in the protein. It allows
mixed tetramers in which some of the subunits are in their weak binding state (T) or
strong binding state (R). Hence, each intermediate state has its mixed structure [5],
as seen in the diagonal in Figure 2 [6]. The KNF model also suggests that in the
absence of ligand, allosteric transitions do not occur [5]. In addition, this model can
describe both negative and positive cooperativity. Negative cooperativity occurs
when T-R interactions are stronger than T-T or R-R interactions.

Positive

cooperativity occurs when T-T and R-R interactions are stronger [8].
In the following years since the initial proposal of these allosteric models, it
has become apparent that neither the KNF nor the MWC model can completely
8

clarify the allosteric behavior of all proteins. Hence, more complex models have
been developed and these models still retain some properties of the initial KNF and
MWC models [9].

Due to the universal equilibrium concept and the simple

formulation, the MWC model has allowed the behavior of many allosteric proteins
using only a few parameters to be determined. On the other hand, the KNF model
involves a more comprehensive understanding of the functional and structural
properties of all the intermediates, as well as end states. Both models are simple
representations that both propose an allosteric mechanism though the modification
of equilibrium conformations of the protein induced by ligand binding. Additionally,
these early models allow the basic parameters for allosteric proteins to be probed
and tested and can lead to some initial insight into how subunit interactions and
ligand binding are coupled to conformational changes in the context of regulatory
behavior [10].
In terms of allosteric receptors, ligand-gated ion channels are allosteric
membrane proteins with multiple subunits composed of a distinct ligand binding
domain and functional ion channel domain. Agonist binding causes conformational
changes that ultimately lead to the gating of the ion channel, or closed and open
states [1].

The thought is that receptors can exist in a variety of discrete

conformational states differing in the ability of that state to produce a response.
More specifically, ligands can interact with the receptor in such a way as to control
the conformational state.

In the context of ligands, a full agonist can elicit a

maximal response, and a partial agonist only elicits submaximal activation even at
saturating concentrations.
9

In Figure 3, two mechanisms to depict allosteric protein behavior of ligandgated ion channels are shown [11]. In Figure 3 A [11], the MWC model suggests
that the receptor is in equilibrium between two conformations, closed (inactive) and
open (active) [4, 7]. The MWC model assumes that conformational states exist
independently of the ligand and that the ligand controls in which conformational
state the receptor exists. Agonist binding stabilizes the receptor in the open
conformation. The ligand can act as an agonist or partial agonist depending upon
its affinity for open or closed state of the receptor and can stabilize the same
conformation states. Full agonists stabilize the open state more effectively than the
partial agonists, thus full agonists produce a greater activation as compared to
partial agonists [12]. Competitive antagonists stabilize the closed state [4, 7]. In
Figure 3 B [13], the KNF model, on the other hand, suggests that the ligand can
induce new conformational states in the receptor [5]. A ligand acts as an agonist,
partial agonist, or antagonist based on its ability to induce conformational states that
are active or inactive. For instance, full agonists stabilize a conformation that fully
activates the ion channel.

In contrast, partial agonists elicit sub-maximal

conformational changes that are not as effective in activating the channel, and
hence partial agonists are not as effective in shifting the closed to the open
equilibrium of the open state in the ion channel. Deactivation of the channel is the
sequential reverse of activation [11]. These models help define the relationship
between ligand binding and conformational changes of the receptor that trigger a
response.

10

Figure 3 Two mechanisms proposed for the conformational changes associated
with ligand gated ion channels. (A) MWC, two-state model and (B) KNF, induced-fit
model [11].
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Ionotropic glutamate receptors are ligand gated ion channels that are
suitable for studying allostery. These receptors couple agonist binding in the ligand
binding domain to channel activation at the ion pore defined by the transmembrane
domain [14]. The AMPA-subtype of the glutamate receptors are important excitatory
neurotransmitter receptors in the mammalian central nervous system and have
been the focus of many wide-ranging structural and pharmacological studies [1416].
III. Structure and Function of AMPA Receptors
Ionotropic glutamate receptors are the main excitatory neurotransmitter
receptors in the mammalian central nervous system. When glutamate binds to the
receptor, cations such as sodium, potassium, and sometimes calcium pass through
the ion channel, facilitating the propagation of the synaptic signal [17-21]. These
receptors have been implicated in learning and memory, the regulation of synaptic
strength, as well as neuropathologies such as epilepsy, ischemia, and amyotrophic
lateral sclerosis [22-30].

Additionally, glutamate receptors have been shown to

engage in various functions outside the central nervous system [31-33].

The

question that this dissertation will focus on is how does a small molecule like
glutamate induce allosteric changes in glutamate receptors and in turn dictate
function.
a. Glutamate Receptor Subtypes
Ionotropic glutamate receptors can be divided into three subtypes, α-amino-5methyl-3-hydroxy-4-isoxazolepropionate (AMPA) receptors, N-methyl-D-aspartate

13

(NMDA) receptors, and kainate receptors, based on their pharmacological
properties in addition to sequence homology (Figure 4) [14]. Each subtype binds
glutamate; however, NMDA is a full agonist for NMDA receptors, AMPA is a full
agonist for AMPA receptors, and kainate is a full agonist for kainate receptors [16].
Although highly homologous, each subtype plays divergent roles in the mammalian
central nervous system. NMDA receptors respond to changes in membrane
potential as well as the required glutamate and co-agonist glycine in the synaptic
cleft [34]. AMPA receptors are the primary mediators of fast excitatory synaptic
transmission in response to glutamate, displaying fast kinetics [35].

Kainate

receptors also play a role in neurotransmission, exhibiting modulatory functions in
the pre- and post-synaptic cell [36].
b. Topology
Native channels formed by tetrameric AMPA receptors consist of four
subunits, GluR1, -2, -3, and -4. Any of the subunits can form the AMPA receptor,
and each subunit alone can form functional homomeric channels. The receptor’s
subunits assemble as back to back dimers [14, 15, 17, 37, 38]. In a single subunit,
AMPA receptors have distinct domains including an extracellular N-terminal domain,
an extracellular ligand binding domain, three transmembrane segments and a reentrant loop that form the transmembrane domain, and an intracellular C-terminus,
as shown in Figure 5 [17, 25, 39, 40].
The N-terminal domain (NTD) shows homology to the bacterial leucineisoleucine-valine-binding protein (LIVBP), a periplasmic binding protein, and has

14

Figure 4 Subtypes of the eukaryotic ionotropic glutamate receptors. The subunits
that compose each subtype is shown [14].
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Figure 5 Detailed schematic of AMPA receptor topology.

(A) AMPA receptor

tetramer. (B) A single subunit contains an extracellular N-terminal domain, an
extracellular ligand binding domain, three transmembrane segments and a reentrant loop that form the transmembrane domain, and a intracellular C-terminus.
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structural similarity to the ligand binding domain of the metabotropic glutamate
receptors. In NMDA receptors, the NTD binds to negative allosteric modulators,
however, in AMPA receptors, no ligands or modulators for the NTD have been
identified. The NTD functions in receptor assembly in AMPA receptors [41-50]. The
ligand binding domain (LBD) of the AMPA receptors is formed by domain 1 (D1)
and domain 2 (D2). The LBD domain has been excised and expressed as a soluble
protein that has been crystallized in various ligated forms [42, 51]; the isolated
ligand binding domain will be discussed in detail in the following section. The AMPA
receptor transmembrane domain shares homology with other ion channel p-loop
sequences and bears a resemblance to a flipped bacterial KcsA potassium channel
pore, as seen in the Mackinnon’s crystal structure. The pore sequence confers its
selectivity properties [3, 52, 53]. The C-terminus varies in size and is an important
site for modulation in targeting and localization of the receptor [54, 55].
c. Crystal Structures of the Isolated Ligand Binding Domain and the Full Receptor
Until December 2009, the crystal structure of the full AMPA receptor had not
been solved. Detailed structural investigations began by exploiting the modular
characteristics of the AMPA receptor and producing a soluble construct of the
GluR2 ligand binding domain formed by two polypeptide sequences, S1 and S2,
that form domain 1 and 2 (D1 and D2) joined by a glycine-threonine linker. The
isolated ligand binding domain protein was easily expressed in large quantities in a
bacterial expression system and was shown to have a similar ligand binding affinity
as the full receptor. Crystal structures of the isolated LBD have been obtained in the
absence of ligand as well as in the agonist, antagonist, and allosteric modulator
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bound states [17, 21, 56-61] . Figure 6 A shows the bi-lobed, cleft structure of the
isolated ligand binding domain dimer in complex with glutamate [56]; the isolated
LBD tends to crystallize as a dimer. The crystal structures of the isolated LBD of
the AMPA receptor have been particularly useful in providing initial insight into the
conformational changes in the ligand binding domain associated with functional
transitions in the receptor; however, these structures are in the absence of the
transmembrane segments, the primary functional portion of the protein.
Is the isolated LBD a good model for the full receptor? This question was
partially answered by Sobolevsky et al.; a crystal structure of the full receptor was
produced, GluA2cryst (Figure 6 B). The receptor was expressed in high quantities in
infected Sf9 insect cells. In order to obtain GluA2cryst, many modifications were
made on the full receptor to increase the resolution of the crystals, including point
mutations, several amino acid deletions at the NTD and the C-terminus, and the
removal of some of the predicted glycosylation sites. Optimization of the detergent
as well as the addition of an antagonist further improved the resolution to 3.6 Å [62].
The determination of the structure revealed further insight into the mechanism of
activation and desensitization of these receptors similar to what is observed in the
isolated LBD.
As described previously, the full length glutamate receptor is modular, where
each of the domains in a single subunit is stacked in layers with the NTD on top,
followed by the LBD, and the transmembrane domain at the base. The NTD forms a
clam-shell similar to the LBD, and they are connected by linker regions.
Additionally, the LBD domain is connected to the transmembrane domain by linker
20

Figure 6 AMPA Receptor crystal structures. (A) Isolated ligand binding domain
dimer in complex with glutamate [56]. (B) Full length AMPA receptor dimer,
GluA2cryst in complex with ZK 00775 [62].
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regions [62]. This arrangement revealed by the crystal structures suggests that
conformational changes at the NTD would affect the conformation of the LBD and in
turn the transmembrane domain, affecting the function of the channel. Although this
has not been shown in the AMPA receptors, several structural implications from
NMDA receptor electrophysiological studies have been revealed [41-50]. Drugs
binding to the NTD cleft in NMDA receptors have been shown to affect the function
of the channel; drugs binding to the AMPA receptor NTD have yet to be identified.
These implications will be further discussed in the Chapter 7.
Moreover, the receptor has a distinctive symmetry and subunit arrangement.
The extracellular domains have an overall two-fold axis of symmetry that relates
one of the NTD dimer to the other dimer, one LBD dimer to the other dimer, and half
of the transmembrane domain to the other dimer. However, the transmembrane
domain has an approximate four-fold axis of rotational symmetry, resulting in a
breakdown of symmetry. In addition to the dimer subunit interactions, there are
extensive interactions across the dimer for both the NTD and the LBD.
Interestingly, there is a subunit crossover between the NTD and LBD, where a LBD
domain in a single subunit is associated with dimer 1, and the NTD of that same
subunit is associated with dimer 2. The crossover could provide a reason as to why
the NTD is important for receptor assembly and stability [62].
Next, the full-length crystal structure reveals that the transmembrane domain
consists of three transmembrane segments (M1, M3, and M4) and a re-entrant loop
(M2), as shown in Figure 6 B. M1 is the first transmembrane segment linked to S1
of the LBD on the outside of the transmembrane domain. M2 is found within the
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pore, and M3 lines the pore and is connected to S2 of the LBD. M4 is on the
outside of the transmembrane domain and is connected to S2 of the LBD. It is
hypothesized that ligand binding results in a conformational change that leads to the
separation of the regions that link the LBD to the transmembrane domain and pulls
apart the M3 segment lining the pore resulting in channel opening, as discussed in
the next section [62].
Based on the crystal structures and functional studies, the hypothesized
mechanism for activation and desensitization is shown in Figure 7 [61]. As
previously mentioned, the ligand binding domain crystallizes as a dimer, and the
dimer interface is formed by contacts in D1. D2 is flexible in order to respond to
ligand binding. In the resting state of the protein, the dimer interface is coupled, no
ligand is bound, and the channel is closed. In addition to crystal structures, smallangle X-ray scattering, NMR (nuclear magnetic resonance), and time-resolved FTIR
(Fourier transform infrared spectroscopy) have been performed on the isolated
ligand binding domain to describe the movement of D1 and D2 upon ligand binding.
These studies suggest that during activation, the agonist binds to D1, and then the
flexible D2 responds to the ligand binding and moves up towards D1 [63-65]. This
is the closed-cleft conformation stabilized by ligand binding as discussed in the next
section. The movement of D2 towards D1 is thought to pull apart the linkers to the
channel thus changing the orientation of the transmembrane domain leading to the
opening of the ion channel.

Upon prolonged presence of glutamate, these

receptors desensitize. In the desensitized state, stress on the linker regions results
in the decoupling of the dimer interface leading to channel closure [56, 66].
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Figure 7 Shown are the hypothesized states of the AMPA receptor in dimeric
form. In the apo state, there is no ligand bound, and the ion channel is closed.
For activation, a ligand such as glutamate binds to the extracellular ligand
binding domain, and D2 moves up towards D1. This movement pulls the linker
to the transmembrane segments apart thus opening the channel.

In the

desensitized state, stress on these linker regions results in the decoupling of the
dimer interface leading to channel closure [61].
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Despite the invaluable information obtained from detailed structures of the
isolated ligand binding domain and the intact receptor, are the crystal structures true
representations of the conformational changes seen in the ligand binding domain of
a functional receptor? I will address this question in this dissertation by studying
conformational changes in the ligand binding domain of a functional receptor in its
dynamic state.
d. Cleft Closure and Activation
Ligand binding alters the conformational state of the AMPA receptor and
produces a functional response, thus describing ligand-gated ion channel allostery.
A comparison of structures of the isolated ligand binding domain of the AMPA
receptor in complex with various ligands has revealed insight into the allosteric
behavior of these receptors. These structural studies in conjunction with functional
studies have provided insight into how ligand binding is coupled to receptor
activation, as shown in Figure 8. In the apo state, the cleft is fully open, and no
current is elicited. Partial agonists, such as kainate, lead to an intermediate cleft
closure (~12 degrees more closed compared to the apo state) with less activation of
the receptor, represented as the peak current elicited from HEK-293 cells. In Figure
8, glutamate, a full agonist of the receptor, results in a large degree of cleft closure
(~20 degrees more closed compared to the apo state) and greater activation of the
receptor when bound. Competitive antagonists stabilize the ligand binding domain
in the open cleft conformation, similar to the apo state, due to steric hindrance, thus
preventing channel opening [56, 59, 60, 67]. Together, this data suggests that there
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Figure 8 Changes seen in the isolated LBD crystal structure and the functional
response seen in the full receptor. The extent of cleft closure correlates to the
extent of receptor activation [56, 59, 68].
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is a strong correlation between the extent of cleft closure and the extent of
activation of the ion channel.
A study of partial agonism by Jin et al., has shed some light onto how
agonists with varying efficacies induce different conformations, hence suggesting
the KNF model, or a multistate induced fit model [5]. Jin and coworkers used a
series of 5-substituted willardiines as a tool to investigate the molecular basis of
partial agonism for AMPA receptors [59]. The willardiine study allowed subtle and
graded conformational changes in the ligand binding domain due to their partial
agonist characteristics to be correlated with the changes in the activity of the ion
channel.

Here, the increasing size of the substituent gave gradually smaller

macroscopic currents (H > F > Br > I) as measured by electrophysiology, so the
size of the substituent is correlated to its ability to activate the channel.

The

induced fit model suggests that partial agonists elicit sub-maximal conformational
changes that are not as effective in activating the channel, which was then
investigated by structural studies. Compared to glutamate, the partial agonists
exhibited less cleft closure. Thus, the increasing size of the 5-substituent yields an
increasing degree of cleft closure [59]. Each partial agonist induces a distinct
conformation, which also suggests the KNF induced fit model [5]. Using single
channel recordings, subconductance states have been found to vary depending on
the characteristics of the agonist. Thus, the degree of cleft closure determines an
individual subunits response the ligand binding and ultimately ion channel opening.
So, each subunit’s opening can then contribute to the opening of higher
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subconductance states as it becomes more favored as the coupling efficiency
increases between ligand binding and activation of the channel [59].
Additionally, mutagenesis has also been used to investigate the allosteric
mechanism of AMPA receptor activation, and one mutant has been found to be an
exception to the current hypothesis for activation. Based on the crystal structures, it
is thought that kainate acts as a partial agonist because it is sterically hindered
between residues Y450 and L650 as it tries to enter the LBD [56, 57]. Mutations at
these residues result in a wide range of activations by agonists and mutations to
smaller, flexible amino acids are expected to increase the activation of kainate [11,
56, 69]. Previous studies of the L650T mutation in an AMPA receptor have been
shown to have a higher activation in response to kainate and a decreased activation
by AMPA relative to the wild-type receptor [70]. Studies using LRET as a molecular
ruler in the Jayaraman laboratory have measured cleft closure distances of the
isolated LBD protein in various ligated states as well as in the presence of
mutations. Activation of the receptor is plotted as a function of cleft closure as
measured by LRET, or distance between a donor and acceptor fluorophores, shown
in Figure 9 [70, 71]. In the wild-type, a similar trend with the crystal structure data
for cleft closure is followed. In the L650T mutant, kainate binding results in a greater
amount of cleft closure than the wild-type displayed by the increased activation for
kainate. However, AMPA in the L650T mutant results in decreased activation yet
has cleft closure greater than that of glutamate, which induces much larger currents
than AMPA [70]. The data with the L650T mutation contradicts the hypothesis that
cleft closure alone determines the extent of activation. This study might suggest
31

Figure 9 Receptor activation plotted as a function of cleft closure distance. Wildtype AMPA receptor (green circles) data shown in response to AMPA, glutamate, 5substituted willardiines (HW, unsubstituted; FW, fluorowillardiine; and IW,
iodowillardiine), kainate, and the apo state. L650T (cyan triangles) data shown in
response to AMPA, glutamate, kainate, and in the apo state [70, 71].
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that there is another mechanism that controls receptor activation. However, it is not
clear if the L650T mutation results in a change in the allosteric mechanism or if the
contradictory results are due to the fact that the mutant was studied in the isolated
LBD and would behave differently in the context of channel segments. This is yet
another example as to why it is important to study conformational changes seen in
the isolated ligand binding domain in a functional receptor in a dynamic state.
e. Dimer Interface Rearrangement and Desensitization
Glutamate binding to the LBD induces a closed cleft conformation and
decreases the stability of the coupling of the dimer interface resulting in dimer
interface rearrangement to relieve the stress placed on the linkers to the
transmembrane domain. Once the dimer interface decouples, the transmembrane
domain can then relax to a more stable conformation, a closed ion channel [61].
Additionally, the stability of the dimer interface can control the stability of the open
channel. Several mutations and allosteric modulators have been found to block
desensitization, as shown in Figure 10. Crystal structures of the isolated LBD have
revealed that cyclothiazide, an allosteric modulator, and mutations in the dimer
interface, such as L483Y, that stabilize the dimer interface block the entrance to the
desensitized state [61, 72-74]. Other allosteric modulators such as aniracetam can
act by stabilizing the open state, closed cleft conformation when a ligand binds [75].
In addition, a mutation outside the LBD was also found to affect desensitization. The
R629E mutation is located in the segment connecting the ligand binding domain to
the transmembrane segments [76]. No structural information exists for this mutant
currently; hence, it is still not clear how this particular mutation, R629E, blocks
34

Figure 10 Shown are isolated LBD crystal structures or diagrams with mutations or
allosteric modulators that can block desensitization.

(A) Two molecules of

cyclothiazide bind to the isolated LBD to stabilize the dimer interface. (B) L483Y
makes favorable interactions across the dimer to keep the dimer interface intact. (C)
Aniracetam binds and stabilizes the closed cleft conformation. (D) R629E is a
mutation outside the LBD and blocks desensitization by an unknown mechanism
[72-74, 76].
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desensitization. Does the mutation allosterically strengthen the dimer interface, or is
the dimer interface decoupled as observed in the wild-type protein but the
decoupling is not communicated to the channel segments due to the mutation?
Structural investigations in a functional receptor are needed in order to answer
these questions. Moreover, desensitization can be increased by introducing
mutations in the LBD that reduce steric hindrance of an agonist in the LBD thus
enhancing cleft closure and consequently destabilizing the dimer interface [11, 64,
77].
Furthermore, the isolated LBD crystallizes as a dimer in all states as shown
in Figure 11 A-C, and until recently there has been no structural information for the
desensitized state [21].

However, an in depth study by Armstrong et al. has

indirectly shown structural aspects of desensitization in a full receptor via
electrophysiology experiments as well as in artificially decoupled crystal structures
of the isolated LBD. Armstrong and coworkers began by introducing cysteines at
the dimer interface of a full receptor and measuring the rate at which modification by
MTSES ((2-sulfonatoethyl) methane thiosulfonate) occurs in various states of the
receptor. One mutant, E486C, proved to be more accessible in the desensitized
state compared to the resting (antagonist-bound) state and open state. Structural
information for the apo state was not obtained because this state has no functional
consequence.

The next step was to introduce various sized bi-functional

crosslinkers in order to confine the dimer interface at different lengths and measure
the functional response to report the state of the receptor. It was shown that short
crosslinkers restrict dimer interface rearrangement and confine the receptor to a
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Figure 11 Intersubunit distances of the different states of the receptor in the
isolated LBD. (A) In the apo state isolated LBD, there is an intersubunit distance of
16 Å between sites S741C suggesting that the interface is coupled. (B) In the open
state, when glutamate and cyclothiazide is bound, the interface is coupled at a
distance of 17 Å. (C) When glutamate is bound in the desensitized state, the
isolated LBD shows a coupled interface at a distance of 17 Å. (D) In the S729C
mutant, the artificially decoupled desensitized-like state shows a decoupled
interface at a distance of 25 Å [56, 58, 74].
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non-desensitizing state, and longer crosslinkers allow the dimer interface to
decouple. Overall, Armstrong reported an intersubunit distance change of around
13 to 16 Å from the open to the desensitized state.

Interestingly, the S729C

mutation, introduced deep in the dimer interface of the isolated LBD to artificially
force the dimer apart, has been showed to be locked in a desensitized state as
determined by electrophysiology. As seen in Figure 11 D, a recent structure of this
mutant shows that the dimer interface is decoupled, consistent with the current
hypothesis for desensitization [58]. However, all of the current structural inferences
for the mechanism of desensitization are based on the structures of the isolated
LBD in the context of the functional studies on the full receptor. Additionally,
because the desensitized state structure has been acquired by artificially
decoupling the dimer interface, this could lead to a more decoupled state than what
is observed in a physiologically relevant state. What is needed to complete the
picture is a study of the conformational changes in the presence of the
transmembrane segments, particularly since desensitization involves more than a
single subunit of the receptor and is stabilized due to the fact that the
transmembrane domain exerts the stress leading to decoupling of the dimer
interface.
f. Significance
Currently, crystal structures provide the foundation for the hypothesized
conformational changes in the ligand binding domain; however, these structures are
limited by crystallographic constraints [21, 56-61, 63, 68, 78].
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desensitization, it is essential to study changes in the ligand binding domain in a
dynamic state. Overall, the objective of these investigations is to determine the
structural changes in the receptor that drive the transition between the resting,
activated, and desensitized state by measuring the conformational changes in the
ligand binding domain of a functional AMPA receptor. Studies to investigate the
structure-function relationship of a functional AMPA receptor will be performed by
using biophysical techniques such as LRET (luminescence resonance energy
transfer) and electrophysiology, in addition to using a series of agonists and
mutations. In this dissertation, I show the conformational changes induced by the
agonist that consequently lead to ion flow in a functional AMPA receptor and
compare the data with the current hypotheses for activation and desensitization.
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Chapter 2—Electrophysiology of the AMPA receptors
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I. The Xenopus laevis oocyte expression system
The Xenopus laevis oocyte is an unfertilized egg cell from the African clawed
frog, shown in Figure 12. The frog itself is easily maintained and can produce
oocytes throughout the year; thousands of oocytes can be extracted from a single
frog. The Xenopus oocyte was first shown to express functional ion channels and
receptors by Miledi et al. in 1982 [79], and since then have become a wellestablished expression system in the area of biophysics for the study of ion
channels.

Xenopus oocytes are large cells, around 1 mm in diameter with a nucleus
around 300 µm across. These cells are arrested during the first meiotic prophase
and can survive for around one week in an isotonic saline solution in the presence
of antibiotics. Their size makes them convenient for manipulations such as injection
of RNA or DNA and electrophysiology experiments.

By injection of RNA/DNA

encoding for the protein of interest, the Xenopus oocytes are able to translate the
exogenous RNA/DNA messages [80] and traffic the protein to the plasma
membrane. The Xenopus oocytes have a high capacity for protein synthesis,
around 200 to 400 ng per day per oocyte. Remarkably, the oocyte allows for many
post-translational modifications needed for protein function.

Additionally, the

Xenopus oocyte correctly assembles and orients multiple subunits into a functioning
protein.
However, there are some limitations of the Xenopus laevis oocyte expression
system.

First, it is a transient expression system, and there is variation in

expression across batches of oocytes, which could affect expression studies when
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Figure 12 The Xenopus laevis expression system. (A) Female African clawed frog,
about 10-12 cm long. (B) An oocyte, about 1 mm in diameter. The oocyte has two
poles, the animal pole (brown) and the vegetal pole (white).
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optimizing the system. Most importantly, endogenous proteins could be expressed
that could interfere with the protein of interest [81, 82].
These limitations would prove to be critical when optimizing the expression
system for future biophysical studies. First, the amount of RNA to inject into each
oocyte and the expression pattern of the oocyte had to be determined. Optimizing
was performed by testing different expression vectors (pcDNA3.1 and pGEM-HE)
and by injecting various concentrations of RNA for two of the proteins of interests;
cell lysates were collected and a Western blot was performed, as shown in Figure
13 A-B. After that, time points for expression for two of the proteins that would be
used for future LRET studies were determined by Western blot, as shown in Figure
13 C-D. The final crucial step was to establish how to control the expression of the
protein of interest without also increasing the background expression of the inherent
proteins of the oocyte that could potentially interfere with the LRET studies, as
discussed in the next chapter. For the LRET studies, the protein of interest would
contain cysteine modifications for the attachments of fluorophores, so any inherent
cysteines from the oocyte would contribute to non-specific LRET signals. Not only
were the oocytes a robust expression system for the AMPA receptors, but the
oocytes could be manipulated further for the LRET experiments. A pre-blocking
procedure had successfully been used on oocytes expressing potassium channels
to block inherent cysteines [83]. Using a similar pre-blocking procedure for oocytes
expressing AMPA receptors, further optimization was performed and the
background, non-specific signal was successfully decreased (see Appendix III for
pre-blocking and expression protocol).
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Figure 13 Western blots for optimizing the Xenopus laevis oocyte expression
system. Cell lysates from 5 oocytes were loaded per well and Anti-GluR4 pAb
(Chemicon) was used as a probe for the protein of interest. For the expression
studies, (A) ∆N*-AMPA-S653C and (B) Histag-∆N*-AMPA-S653C protein was
collected after 24 hours of expression. RNA (30 ng) encoding for (A) ∆N*-AMPA
and (B) Histag ∆N*-AMPA-S653C was injected and collected for time point studies.
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II. The two-electrode voltage clamp
Much of what is known about the properties of ion channels in cell
membranes has come from experiments using a voltage clamp, which allows the
control of membrane potential in order to measure ion flow as electrical currents.
This method was first developed by Cole et al. (1949) and Hodgkin et al. (1952) for
use with the squid giant axon [84-86]. Since then, many variations of the technique
have been developed, namely the two-electrode voltage clamp—the focus of the
rest of this chapter. Now that the oocyte expression system had been established
for the AMPA receptor, the protein function could be characterized by this
technique.
Oocytes are biological circuits, and as mentioned previously, the voltage clamp
controls the membrane potential of the oocyte.

The membrane potential is

measured in volts, and voltage (V) is attained by the charge separation across the
membrane.

Current (I), on the other hand, is generated by the movement of ions

across the membrane. The basic configuration of the two-electrode voltage clamp
is shown in Figure 14 [87]. First, two electrodes are impaled into the oocyte. One
electrode is the voltage electrode, where the membrane potential is measured
relative to the ground. The second electrode is the current electrode, which is
capable of injecting current into the oocyte.

A holding voltage, or command

potential is set (-60 mV) and the voltage clamp uses negative feedback to maintain
the oocyte at this voltage. Whenever the oocyte deviates from the holding voltage
(as in a ligand is added, the channel opens, and ions flow through), the feedback
amplifier detects the difference between the command potential and the membrane
49

potential of the oocyte. It then subtracts the membrane potential from the command
potential, and sends out an output signal to the current electrode in order to
maintain the holding potential. The signal equal and opposite to the ionic current is
produced and this can be measured, giving an accurate reproduction of the currents
flowing across the membrane [81, 87]. These type of experiments are performed
for each AMPA receptor expressed in oocytes that has been modified for the LRET
experiments in order to establish that the mutations such as cysteine modifications
or the additions of histidine tags do not perturb the function of the receptor.
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Figure 14 The two-electrode voltage clamp.

The system allows control of the

membrane potential in order to measure ion flow as electrical currents. The oocyte
sits in a small-volume chamber where ligands can be profused quickly and removed
to the waste [87].
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Chapter 3— Fluorescence Spectroscopy Methods
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I. Introduction to Fluorescence
Luminescence is defined as the emission of light by a molecule due to either
chemical, mechanical, or physical processes. Photoluminescence, or luminescence
due to ultraviolet and visible (UV-Vis) light used to excite a molecule, can be
subdivided further into fluorescence and phosphorescence [88]. An introduction to
fluorescence is provided here in order to describe the foundation of the
fluorescence spectroscopy technique used in this dissertation.

Fluorescence

spectroscopy is an important tool in biological studies with uses ranging from the
detection of a protein to investigations of the structure of a protein.
In order to describe fluorescence and phosphorescence, the two processes
are depicted by the Jablonski diagram as seen in Figure 15 to show the various
energy levels involved [89].

When a molecule at ground state (S0) absorbs a

photon of energy, it is excited to one of many vibrational states of a higher energy
electronic state (S1 or S2). Excitation occurs on the femtosecond timescale. Next,
the excited state electrons relax to the lowest energy level by internal
conversion/vibrational relaxation on the picosecond timescale. On the nanosecond
timescale, decay to the ground state (S1 to S0) and release of a photon describes
fluorescence. The excitation energy is greater than the emission energy due to the
loss of energy during this process, thus the excitation wavelength is shorter than the
emission wavelength; this principle is referred to as Stoke’s shift. The timescale for
a molecule to absorb a photon at a particular wavelength and emit a photon at a
longer wavelength is the fluorescence lifetime. During phosphorescence, however,
the excited electron can go through intersystem crossing from the S1 to the triplet
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Figure 15 The Jablonski Diagram [89]. Upon the transition from S1 state to S0 state,
fluorescence occurs.

After intersystem crossing, upon the transition from the

forbidden T1 state to S0 state, phosphorescence occurs [88].
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state T1, and then transition from the T1 state to the S0 state, a forbidden transition.
Thus, phosphorescence occurs on the millisecond timescale, much slower than
fluorescence.
Molecules that are capable of fluorescence are also known as fluorophores.
Fluorophores can be classified by their excitation and emission properties, which
stem from their molecular structure [88]. The organic dyes that are used in this
work include ATTO465-maleimide and (Ni-NTA)2Cy3, which contain a rigid ring
structure capable of fluorescence and do not phosphoresce.

The maleimide-

derived fluorophores is commercially available, and the Ni-NTA derivative of Cy3 is
synthesized (as described in Kapanidis et al. [90]); the fluorophores are easily
attached to the protein of interest by chemical modification. The organic dyes will
serve as acceptor molecules tagged to the protein of interest for future structural
studies, in which their fluorescent properties will be exploited. The lifetime of these
fluorophores when excited are on the nanosecond timescale; these short-lived
lifetimes is an advantage for the temporal resolution of lifetimes discussed later in
this chapter. Another advantage of using these organic dyes include high quantum
yields, or the ratio of photons emitted to the photons absorbed, which makes these
molecules very bright. These molecules also have high extinction coefficients as
well as broad emission spectra [88].
II. Fluorescence Resonance Energy Transfer
Fluorescence Resonance Energy Transfer (FRET) is a technique that is
commonly used to measure distances between two points separated by
approximately 15 to 100 Å, and has been widely used to study large scale
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conformational changes in proteins, the focus of this dissertation [91-93]. In order
to study protein conformational changes, a donor fluorophore and an acceptor
fluorophore are tagged to the protein such that a conformational change will be
reflected. In order for FRET to occur, the donor fluorescence must overlap with the
absorption of the acceptor, as seen in Figure 16 A. Additionally, the transition
dipole moments of the fluorophore pair should be approximately parallel (Figure 16
B). Next, the distance between the donor and acceptor fluorophore must be less
than 100 Å (Figure 16 C). Once these conditions are met by the fluorophore pair,
FRET experiments can be performed on the protein labeled with the fluorophores
[94]. The donor fluorophore is excited and the excitation energy can either return to
ground state thus emitting a photon or FRET can occur and the energy is
transferred to an acceptor. The transfer occurs by the interaction of the transition
dipole moments between the donor and acceptor. The efficiency of this transfer can
be calculated into distances that reflect conformational changes. The theory began
with Forster’s calculations for FRET [95], which have further been modified by
Selvin [92] and discussed below.
The efficiency of energy transfer (E) can be calculated by the equation 1:
E=

1
1+ (R/Ro)6

.

eq. 1

R is the distance between the fluorophores and R0 is the distance where energy
transfer is 50%. This equation reveals how sensitive this technique is for measuring
distances, as seen by the distance, R, to the sixth power.
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Figure 16 Conditions for FRET. (A) FRET occurs when there is a spectral overlap
between the donor excitation and the acceptor absorption. (B) The dipole moments
of the fluorophores must be approximately parallel for FRET to occur. (C) FRET is
distance dependent, so the fluorophores should be less than 100 Å apart [94].
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By slightly increasing the distance between the fluorophores, R, the efficiency, E,
dramatically drops, as shown in Figure 17. Thus, by keeping R close to R0, the
technique can sensitively detect changes in distance.

R0 is then calculated by

equation 2:

R06 =

8.785 * 10 −5 * κ 2 * φ D * J
.
n4

eq. 2

In equation 2, κ2 is the orientation factor that accounts for the direction of the
dipoles of the donor and the acceptor fluorophores. In most cases, the factor is
assumed to be 2/3, when the fluorophores are not polarized and free to occupy all
angles. This factor is a major source of error in this calculation. However, this
issue is addressed in LRET and will be discussed in the next sections. Next, the ΦD
is the quantum yield of the donor fluorophore. The n is the refractive index, and in
this case the refractive index for water is 1.3. The J is the spectral overlap integral
between the donor fluorescence and the acceptor absorption and is calculated by
equation 3:
J=

∑F

D

i

( λi ) * ε A ( λi ) * λi

∑F

D

( λi )

4

.

eq. 3

i

The FD(λ) is the fluorescence spectrum and εA(λ) is the molar extinction coefficient
of the acceptor. Additionally, λ is the wavelength.
A modified FRET technique called Luminescence Resonance Energy
Transfer (LRET) is utilized in this dissertation to study conformational changes in
the ligand binding domain of a functional AMPA receptor and has been successfully
used to study conformational changes in both soluble and membrane bound
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Figure 17 FRET Efficiency versus Distance.

Sensitive distance changes are

obtained when the distance between the fluorophores, R, is near the R0, where the
efficiency of energy transfer is 50% [94].
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proteins [70, 96]. There are several advantages of using LRET instead of FRET;
however, the basic principles of FRET are still utilized. These details are discussed
in the next section.

III. Luminescence Resonance Energy Transfer
The

recently

improved

FRET

technique

is

referred

to

as

LRET

(Luminescence Resonance Energy Transfer) because the donor is luminescent [92,
97].

In the LRET technique, a luminescent lanthanide donor such as terbium

chelate is excited and transfers energy to a fluorescent acceptor dye, such as the
organic dyes discussed previously, ATTO465-maleimide, and (Ni-NTA)2Cy3.
LRET has a number of improvements including greater distance range; temporal
resolution of signals; a decrease in error due to the orientation factor; and multiple
distances can be determined for a single system [92].
The advantages of using LRET are due to the inherent properties of terbium
chelate, the donor. First, terbium chelate has a high quantum yield. Additionally,
terbium chelate is isotropic, which greatly reduces the error associated with the
FRET calculations discussed above [92, 97].

Terbium chelate has four sharp

emission peaks that allow spectral separation of donor and acceptor fluorescence,
shown in Figure 18 [98]. This also allows a wide range of acceptors to be paired
with terbium chelate to give a variety of R0 values to choose from. This feature also
reduces the background by choosing an acceptor that fluoresces where terbium is
dark. Most importantly, terbium chelate has a long lifetime in the microsecond to
millisecond timescale compared to the organic dyes used as acceptors, which have
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Figure 18 Terbium chelate excitation and emission spectrum. Terbium is excited at
337 and the 4 sharp peaks of the fluorescence spectrum at 490, 546, 585, and 620
nm are shown [98].
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a nanosecond lifetime. The long lifetime allows temporal separation of the acceptor
only, donor only, and LRET signal. The donor only sample does not contribute to
the LRET signal since LRET is measured at the wavelength of the acceptor,
referred to as sensitized emission. Thus, the sensitized emission is due to the
acceptor gaining fluorescence from the donor. The acceptor only sample has a
nanosecond lifetime, while the LRET lifetime is long lived in the microsecond to
millisecond timescale. The equation for distance calculations based on lifetimes is
shown below:
 τ DA
R = R0 
 τ D − τ DA





1/ 6

.

eq. 4

In equation 4, the time constants for donor fluorescence decay in the absence of the
acceptor, τD, and the sensitized emission of the acceptor due to the energy transfer
from the donor, τDA, are measured in order to determine the distance between the
fluorophores based on lifetimes [92].
This allows for an investigation were the donor and acceptor can be
introduced into a system with multiple tagging sites that leads to a complex mixture.
For example, in a cysteine light protein, multiple cysteines can be introduced and
can be labeled by maleimide derivatives of both a donor and acceptor. Thus by
manipulating the concentrations of donor to acceptor ratios, distances between two
cysteines can be determined. Cha et al. has successfully performed these types of
LRET investigations to study intersubunit distances in the potassium channel [83].
Additionally, another LRET labeling strategy (a histag to serve as the acceptor
tagging site for (Ni-NTA)2Cy3 and a cysteine site for the maleimide derivative of
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terbium chelate) has been used to study cleft closure conformational changes in the
isolated ligand binding domain of the AMPA receptor [70].
IV. Instrumentation
Two types of fluorescence instruments were utilized in measuring the
fluorescence lifetimes for the determination of large scale conformational changes
in AMPA receptors.
components:

a

Basic fluorescence spectrometers have three fundamental

light

source,

a

sample

compartment,

and

a

detector.

Monochromators are also used to adjust excitation and/or emission wavelengths
[88].
The first fluorescence lifetime spectrometer used is the TimeMaster Model
TM-3/2003 from Photon Technology International (P.T.I., NJ). The light source is a
pulsed 337 nm nitrogen dye laser in which a fiber optic cable connects the light
source to the sample compartment.

In this system, the sample is placed in a

cuvette. The TimeMaster contains an emission monochromator with variable slit
widths in addition to a stroboscopic detector. The Felix 32 software provided with
the TimeMaster was used to collect data and then studied using Origin, a
mathematical graphing software (OriginLab Corp., MA) [96]. This system was
accurate and used for the cleft closure distance measurements; however, it would
not be ideal for the type of experiments using a 4:1 labeling ratio of donor:acceptor
used to measure intersubunit distance measurements.

This ratio drastically

reduces the signal (sensitized emission of the acceptor), and this instrument has
limitations in sensitivity. Because the signal from the labeled functional receptor
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expressed in oocytes was small with a suboptimal signal-to-noise ratio, a more
sensitive instrument was used.
The next spectrometer used for fluorescence lifetime measurements is the

QuantaMaster Model QM3-SS also from Photon Technology International.

The

sample holder was also a cuvette; a Peltier TE temperature sample controller holds
the sample at 15 °C. A high powered, pulsed xenon lamp serves as the light
source. An excitation and emission monochromator control the desired wavelengths
and are also equipped with variable slit widths to further control the transmitted light.
Ultimately, the fluorescence signal reaches the detector, or the PMT (photomultiplier
tube). Fluorescan software from PTI is used to collect the data and is analyzed
using Origin.
Donor-only lifetimes were measured at the wavelength of donor emission
and sensitized emission lifetimes of the acceptor were collected in dark regions of
donor emission. Three individual data sets were collected for statistical analysis
and the averages were fit to collect the lifetimes. It should be noted that individual
sets are also fit in order to show that each set exhibit similar lifetimes. These
lifetimes were then used to calculate the distances as mentioned in the previous
section.
V. Anisotropy of the Fluorophores
In order to evaluate the error associated with the distances obtained by
LRET, the orientation factor, κ2, must be analyzed in detail. A fluorophore becomes
polarized when exposed to polarized light. Anisotropy is defined as extent of the
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polarized component of the emission of the fluorophore [88].

The equation for

anisotropy, r, is shown below:

r=

IVV – G * IVH
IVV + 2 * G * IVH

.

eq. 5

In equation 5, IVV is the intensity measured when both the excitation and emission
polarizers are positioned vertically.

IVH is the intensity measured when the

excitation polarizer is positioned vertically and the emission polarizer is horizontal.
The G factor is the ratio of IHV to IHH. IHH is the intensity measured when both the
excitation and emission polarizers are positioned horizontally. IHV is the intensity
measured when the excitation polarizer is positioned horizontally and the emission
polarizer is vertical. The polarizer positions are demonstrated in Figure 19 [88]. For
fluorophores, the polarized emission becomes less polarized due to rotational
diffusion; thus, the anisotropy is low.

However, as mentioned previously, the

anisotropy for the lanthanide donor, terbium, is zero [92, 97]. This is the case
because the lifetime for terbium is in the microsecond to millisecond timescale,
much greater than an organic dye, which is in the nanosecond timescale.

Thus,

the source of error for the LRET experiments is the orientation factor from the
acceptor fluorophore, which is greatly affected by the attachment of the fluorophore
to the protein. Thus, the errors in absolute distances reported in this dissertation
are from equation 2 for the R0 value which includes the orientation factor. These
errors are calculated from the anisotropy experiments on the fluorophores using
equations summarized in Haas et al [99].

Additionally, the anisotropy

measurements reveal that in different ligated states, the anisotropy remains the
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same for a donor-acceptor tagged protein, thus the relative errors between each
ligated state is expected to be less.
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Figure 19 A schematic representation of the anisotropy experiments. Polarized
light excites the fluorophore in the sample holder and then the polarized
fluorescence emission is detected. The position of the polarizers, vertical (V) and
horizontal (H), are shown [88].
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Chapter 4—LRET Part I: Cleft Closure Conformational Changes in the Ligand
Binding Domain of a Functional AMPA Receptor
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I. Testing the activation hypothesis
As discussed in the first chapter of this dissertation, the changes seen in the
isolated ligand binding domain along with functional data from the full receptor
suggest that the extent of cleft closure correlates with the extent of activation [56,
59, 60, 67]. The hypothesis for activation describes how the conformational state of
the ligand binding domain is coupled to the functional response of the receptor.
This chapter aims to test this hypothesis by measuring the cleft closure distance
change in response to various agonists in a functional AMPA receptor and correlate
these changes seen with functional data. Why is this investigation important if an
extensive amount of data is readily available from the isolated LBD of the receptor
and the full receptor structure was recently solved? Although the isolated LBD has
provided initial insight into the functional transitions of the receptor once it is
activated, the isolated LBD is in the absence of the functional portion of the
receptor, the transmembrane segments. These isolated LBD structures in general
were shown to be limited by the lack of desensitized state structure; only when the
isolated LBD was artificially decoupled, was a desensitized-like structure obtained
[58]. While the crystal structure of the full receptor has been recently solved, the
crystal structures are not in a dynamic state; the receptor is confined to
crystallographic constraint [62].

Thus, cleft closure conformational changes must

be investigated in a functional receptor in a dynamic, near physiological state.
Previously, the Jayaraman lab has investigated conformational changes in
the ligand binding domain of a functional AMPA receptor expressed in HEK-293
cells. The LRET strategy used included the use of GFP, green fluorescent protein,
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fused to the N-terminus of an AMPA receptor to serve as an acceptor fluorophore
[100]. However, GFP is a bulky protein that is similar in size to the ligand binding
domain of the receptor [101]. Thus, the conformational changes seen were possibly
restricted in the AMPA receptor fusion protein. In this chapter, the LRET technique
was cleverly modified in order to study conformational changes in a functional
AMPA receptor in a physiologically relevant state.
II. Establishing LRET studies in a non-purified system
LRET is an excellent tool to study conformational changes in protein in their
dynamic state [92]. A significant impediment for the generalized use of LRET based
methods for determining conformational changes in proteins lies in designing
unique sites that can be tagged with donor and acceptor fluorophores. The current
strategies used have several limitations such as the large size of the fluorophores
as is the case with GFP-like proteins [102] or difficulty in incorporating the site such
as with unnatural amino acids [103]. The use of histidine tags as possible
recognition site by a nickel-nitrilotriacetate (Ni-NTA) based fluorophore shows
significant promise due to their small size and simple introduction. However their
use has been somewhat restricted because of the non-specific background signal
that arises from the non-specific binding due to the weak non-covalent interactions
between the nickel-nitrilotriacetate and the histidine tag [90]. Reduction of the
background fluorescence or quantification subtraction of the background FRET
would greatly diversify and expand the applicability of this method for protein
conformation determination. This modified method allows the determination of the
LRET between the Ni-NTA fluorophore bound to the histidine tag and a second
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target site by quantitatively determining the non-specific background LRET. For
these investigations, a protease recognition or stop site between the histidine tag
and the protein of interest is introduced. This allows the histidine tag to be cleaved
off, thus removing the acceptor site for LRET experiments. The initial total LRET
signal is obtained from the sample first.

The LRET signal measured after the

cleavage of the histidine tag is the background non-specific signal.

The non-

specific signal is then subtracted from the total signal in order to obtain the specific
LRET signal produced only from the protein of interest. The usefulness of the
technique lies in the fact that the protein does not have to purified, which allows for
studying proteins in a near physiological state.
The applicability of this strategy was first shown by examining the
conformational changes in the isolated ligand binding domain of the GluR2 subunit
of the AMPA receptors expressed in E. coli.

The cleft closure conformational

distance changes have been intensely investigated by crystallography as well as by
LRET by the Jayaraman lab [56, 59, 60, 67, 70, 104], thus the data from modified
LRET investigations can be compared to previous data published to show the
feasibility of the modified LRET technique. This cleft closure conformational change
is reflected as a 6 Å distance change between the N-terminus and residue 652 in
the isolated GluR2-LBD crystal structure, thus making these good sites to be tagged
with donor and acceptor fluorophores [56]. For the LRET investigations, a histidine
tag was introduced at the N-terminus followed by a thrombin digestion sequence
prior to the isolated GluR2-LBD sequence, and a cysteine was introduced
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Figure 20 A schematic representation of the experiments performed with the
isolated ligand binding domain. A histag and a thrombin cleavage sequence were
introduced at the N-terminus and a cysteine was introduced at site S652 to serve as
acceptor and donor sites, respectively, to provide a direct readout of cleft closure.
LRET was measured between the donor and acceptor fluorophores before and after
the addition of thrombin.
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at site 652, as shown in Figure 20. This labeling strategy serves as a direct readout
of cleft closure.
In order to compare a purified and non-purified system, the protein was
expressed in Origami B cells (Novagen) and the non-purified supernatant of the cell
lysate was collected for LRET experiments; additionally, the cell lysate was then
further purified on a Ni-NTA HiTrap affinity column and collected for LRET
experiments. Further details on protein production and purification are explained in
detail in Appendix VIII.

As shown in Figure 21, before performing LRET

experiments, a SDS-PAGE experiment was performed on the supernatant of the
cell lysate, the purified isolated LBD, and protein samples subjected to thrombin
digestion (2.5 U per mg of protein) collected at different time points.

This

experiment was performed in order to determine the time it takes for complete
thrombin digestion to occur so that the histag/acceptor site is removed from the
protein.
For LRET experiments, the non-purified supernatant and the purified protein
were labeled with the donor terbium chelate (Invitrogen) and the acceptor (NiNTA)2Cy3 fluorophores [90]. First, the lifetime of the sensitized emission of the
acceptor in the presence of the donor was measured to determine the total signal.
To the same samples, thrombin was added and the sample was digested for 24
hours at 4 °C. The lifetime of the sensitized emission of the acceptor in the
presence of the donor was measured post-thrombin digestion after the removal of
the acceptor site to account for the non-specific background LRET signal. The
before and after LRET signals were then subtracted in order to obtain the specific
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Figure 21 SDS-PAGE of GluR2 isolated LBD. Non-purified protein (supernatant)
and purified protein samples were subjected to 4, 6, and 24 hour thrombin digestion
at 4 °C. After the histag is removed by thrombin digestion, a decrease in the size of
the protein is detected [96].
Reproduced in part with permission from Gonzalez, J., Rambhadran, A., Du, M.,
Jayaraman, V. 2008. LRET investigations of conformational changes in the ligand
binding domain of a functional AMPA receptor. Biochemistry 47:10027-10032.
Copyright 2008 American Chemical Society.
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LRET signal between the donor and acceptor fluorophores tagged to the protein of
interest.
For the apo state non-purified supernatant and the purified protein, the
before and after thrombin digestion LRET signal for the sensitized emission of the
acceptor is shown in Figure 22 A and B, respectively. It is clearly shown that there
is a smaller non-specific background signal (post-thrombin digestion) coming from
the purified isolated GluR2-LBD compared to the non-purified GluR2-LBD. The
total signal and non-specific were then subtracted in order to obtain the specific
lifetimes coming from the protein of interest. The donor-only lifetime and the lifetime
obtained after the subtraction to represent the specific signal coming from the
protein of interest could be well represented by a single exponential decay
corresponding to a single distance measured (Figure 22, Table 1). The distance
measured is between the fluorophores and not the protein itself, thus the trends in
lifetimes corresponding to distances are studied. For the non-purified supernatant,
the apo, unligated state had a lifetime of 240±20 µs and the glutamate-bound state
had a lifetime of 145±10 µs (Figure 22, Table 1). For the purified isolated GluR2LBD, the lifetimes for the subtracted LRET was 210±10 µs for the apo state and
130±10 µs for the glutamate-bound state as shown in Figure 21 and Table 1. The
specific LRET lifetimes obtained for the non-purified supernatant and the purified
protein was similar, thus suggesting that the subtracted lifetimes obtained using the
modified LRET technique are unique to the isolated GluR2-LBD. Furthermore, the
distance change as measured from the LRET investigations shown in Table 1
between the apo (51±2 Å) and glutamate-bound state (46±2 Å) was 5 Å in
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Figure 22 LRET lifetimes for the isolated LBD. The before and after thrombin
digestion signal (sensitized emission of the acceptor measured at 575 nm) is shown
for the apo state of (A) the supernatant from E. coli cell lysate and (B) purified
GluR2-LBD. The before and after digestion with thrombin signal was subtracted for
both the apo and glutamate-bound states for (C) the supernatant from E. coli cell
lysate and the (D) purified GluR2-LBD [96].
Reproduced in part with permission from Gonzalez, J., Rambhadran, A., Du, M.,
Jayaraman, V. 2008. LRET investigations of conformational changes in the ligand
binding domain of a functional AMPA receptor. Biochemistry 47:10027-10032.
Copyright 2008 American Chemical Society.
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Table 1 Fluorescent Lifetimes and Distances for GluR2-LBD and Histag-∆N*AMPA-S653C Receptors.

Lifetimes of the donor-only labeled protein and the

subtracted lifetimes for the sensitized emission of the acceptor in the presence of
the donor with the corresponding distances for the conformational states of the
AMPA receptor for the apo, glutamate, and kainate (Histag-∆N*-AMPA-S653C
Receptors) bound states [96].
Reproduced in part with permission from Gonzalez, J., Rambhadran, A., Du, M.,
Jayaraman, V. 2008. LRET investigations of conformational changes in the ligand
binding domain of a functional AMPA receptor. Biochemistry 47:10027-10032.
Copyright 2008 American Chemical Society.
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Ligand
Protein

Donor

Sensitized

lifetime

emission

Distance

(µs)

lifetime (µs)

(Ǻ)

GluR2-LBD supernatant

Apo

1590±45

240±20

51±2

GluR2-LBD supernatant

Glutamate

1575±60

145±10

46±2

1490±40

210±10

51±2

1455±65

130±10

46±2

1575±60

260±25

51±2

1580±45

165±15

47±2

1585±45

190±10

49±2

GluR2-LBD purified

Apo

protein
GluR2-LBD purified

Glutamate

protein
histag-∆N*-AMPA-S653C

Apo

receptor
histag-∆N*-AMPA-S653C

Glutamate

receptor
histag-∆N*-AMPA-S653C

Kainate

receptor
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experiments performed with the supernatant as well as with the purified protein and
in good agreement with the crystal structure based distances, showing that this
technique can be used to study relatively small distance changes associated with
conformational changes in the protein.
III. LRET Results and Discussion
Since the modified LRET experiments were successful in probing cleft
closure conformational changes in the isolated ligand binding domain of GluR2 in a
non-purified system, the technique was extended to investigate conformational
changes in the ligand binding domain of a functional AMPA receptor in response to
various ligands.
a. Modified AMPA receptors
A similar LRET labeling strategy from the isolated GluR2-LBD was also used
in the functional AMPA receptors LRET investigations to probe cleft closure
distance measurements. In order to introduce cysteines at specific sites, the GluR4
subytpe of the receptor has been modified such that there are no accessible
cysteines by removing the N-terminal domain (which has previously been shown to
not affect the receptor activation) and by mutating two of the accessible,
extracellular cysteines (C426 and C529) to serines (this construct will be referred to
as ∆N*-AMPA receptors). A hexa-histidine tag was introduced at the N-terminus of
the ∆N*-AMPA receptor and a glutamine residue is introduced between the histag
and the ∆N*-AMPA receptor sequence, as shown in Figure 23. For cloning details,
see Appendix I. The introduction of the glutamine allows for the cleavage of the
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Figure 23 Diagram of the modified LRET experiments performed on modified
AMPA receptors expressed in oocytes.

The GluR4 subunit was modified by

introducing a cysteine at site 653 and a hexa- histidine tag at the N-terminus with a
glutamine residue between the histidine tag and the AMPA receptor sequence
(histag-∆N*-AMPA-S653C). LRET is measured before and after the addition of
TAGZyme, an enzyme that removes the histag and stops at the glutamine [96].
Reproduced in part with permission from Gonzalez, J., Rambhadran, A., Du, M.,
Jayaraman, V. 2008. LRET investigations of conformational changes in the ligand
binding domain of a functional AMPA receptor. Biochemistry 47:10027-10032.
Copyright 2008 American Chemical Society.
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histag with TAGZyme (Qiagen), a dipeptidase enzyme that digests the histidine tag,
and the cleavage stops when the enzyme encounters a glutamine. This allows for
measurements of the LRET signal after cleavage of histag, the background nonspecific LRET signal.
b. Receptor characterization by electrophysiology
The modified histag-∆N*-AMPA-S653C protein was expressed in oocytes by
injecting the oocytes with RNA encoding the modified protein [105]. After injection
the oocytes were incubated at 12 °C to prevent surface expression of the receptor.
After for 2-3 days, the oocytes are pre-blocked with β-maleimidopropionic acid for
one hour. This procedure was first established in potassium channels where
blocking inherent cysteines of the oocyte increases the specificity of the tagging of
the receptor [83] . The blocked oocytes were placed at 18 °C for 24 to 36 hours
allowing for the expression of the receptors. At the end of 24-36 hours, the oocytes
were labeled with 2 µM of maliemide derivative of terbium chelate for one hour.
The excess fluorophore was then washed with buffer. These oocytes were used for
electrophysiological measurements, while the oocyte membrane preps obtained by
lysis of these oocytes were used for radioactive binding and LRET measurements
(see Appendix III Membrane Preparation for protocol). The acceptor fluorophore,
(Ni-NTA)2Cy3, is added to the membrane preparations for LRET investigations.
In order to establish the functionality of the modified AMPA receptor, histag∆N*-AMPA-S653C, expressed in oocytes, radioactive binding and two-electrode
voltage clamp were performed (Figure 24). Membrane preparations of several
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Figure 24 Functional studies of histag-∆N*-AMPA-S653C. (A) Radioactive [3H]
AMPA binding studies with membrane preparations of oocytes expressing histag∆N*-AMPA-S653C. (B) Current traces from oocytes expressing histag-∆N*-AMPAS653C receptors in the presence of 1 mM glutamate and 1 mM kainate with 100 µM
cyclothiazide to block desensitization. (C) Maximum currents recorded at various
glutamate concentrations in the presence of cyclothiazide for the histag-∆N*-AMPAS653C receptors formed a dose response curve [96].
Reproduced in part with permission from Gonzalez, J., Rambhadran, A., Du, M.,
Jayaraman, V. 2008. LRET investigations of conformational changes in the ligand
binding domain of a functional AMPA receptor. Biochemistry 47:10027-10032.
Copyright 2008 American Chemical Society.
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oocytes expressing the modified receptor were obtained for the radioactive binding
experiments. The Kd for the wild type receptor was established as 40±15 nM [11],
and the Kd for histag-∆N*-AMPA-S653C receptor was measured as 88±10 nM,
establishing that the binding properties of the modified receptor are similar to the
wild type receptor (Figure 24 A). The histag-∆N*-AMPA-S653C modified receptor
expressed in oocytes was further characterized by performing two-electrode voltage
clamp in order to study the currents elicited. Currents were recorded in the
presence of agonist, 1 mM glutamate or 1 mM kainate, with the addition of 100 µM
cyclothiazide added to block desensitization (Figure 24 B). Peak currents were
analyzed at various concentrations of glutamate in the presence of cyclothiazide,
and normalized to currents collected at 10 mM glutamate. A dose response curve
was obtained for the histag-∆N*-AMPA-S653C modified receptor. In Figure 24C,
the EC50 for the modified receptor is 310 µM, and the EC50 for the wild type receptor
(data not shown) is 250 µM. These results reiterate the similarity between the
histag-∆N*-AMPA-S653C and the wild type receptor indicating that the mutations
and fluorophores introduced for the LRET investigation do not perturb the function.
c. LRET Studies
The modified AMPA receptor expressed in oocytes was tagged with the
maliemide derivative of the terbium chelate and the Ni-NTA derivative of Cy3 is
added to the membrane preparations of around 300 oocytes. The total LRET signal
is recorded before the addition of thrombin and the non-specific LRET signal is
measured after the digestion with TAGZyme to remove the histag. In Figure 25, the
effectiveness of the TAGZyme enzyme removing the histag was tested by
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Figure 25 Membrane preparations of histag-∆N*-AMPA-S653C expressed in
oocytes were collected before and after TAGZyme digestion. Samples were run on
SDS-PAGE in denaturing conditions. Western blots were either probed with (A)
Anti-GluR4 and (B) Anti-Pentahisitidine antibodies [96].
Reproduced in part with permission from Gonzalez, J., Rambhadran, A., Du, M.,
Jayaraman, V. 2008. LRET investigations of conformational changes in the ligand
binding domain of a functional AMPA receptor. Biochemistry 47:10027-10032.
Copyright 2008 American Chemical Society.
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performing Western blots on membrane preparations from oocytes expressing
histag-∆N*-AMPA-S653C receptor. Samples were incubated at 25 °C with
TAGZyme at various time points. The blots were probed with either anti-GluR4 or
anti-Pentahistadine antibodies. The results indicate that the receptor is successfully
probed after incubation; however, the histag is no longer detected after 3 hours of
incubation with TAGZyme.
Figure 26 A shows the lifetimes for the sensitized emission of the acceptor in
the presence of the donor measured before and after the addition of TAGZyme in
the apo state of the receptor. Additionally, in Figure 26 B, the difference in the
LRET lifetime before and after addition of the TAGZyme is shown for the apo,
kainate-bound, and glutamate-bound states. The subtracted LRET signal can be fit
to a single exponential decay, thus suggesting a single lifetime of 260±25 µs (apo),
165±15 µs (kainate-bound state), and 190±10 µs (glutamate-bound state). Parallel
experiments were also performed on donor-only labeled samples and no significant
changes were observed in the lifetimes between the receptor states, suggesting
that the changes observed in the LRET signal are not due to changes in the
environment of the fluorophore but due to changes in the donor:acceptor distance.
Hence, the histag-∆N*-AMPA-S653C receptor serves as a probe to detect distance
changes in cleft closure.

Using the lifetimes and the R0 values, the absolute

distances calculated are shown in Table 1 for each state of the receptor. The
absolute distances for the apo, kainate-bound state, and the glutamate-bound state
are 51±2 Å, 49±2 Å, and 47±2 Å, respectively. Furthermore, the distance
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Figure 26 LRET lifetimes for the histag-∆N*-AMPA-S653C receptor. (A) The before
and after TAGZyme treatment signal (sensitized emission of the acceptor measured
at 575 nm) is shown for the apo state.

(B) The before and after TAGZyme

treatment signal was subtracted for the apo, kainate-bound state, and the
glutamate-bound state [96].
Reproduced in part with permission from Gonzalez, J., Rambhadran, A., Du, M.,
Jayaraman, V. 2008. LRET investigations of conformational changes in the ligand
binding domain of a functional AMPA receptor. Biochemistry 47:10027-10032.
Copyright 2008 American Chemical Society.
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change as measured from the LRET investigations between the apo and glutamatebound state is 4 Å, and the distance change between apo and kainate-bound state
is 2 Å. Although the absolute distance change from apo to kainate-bound state is
within the error of the measurements, the trends should be noted. As previously
discussed, the distances reported in this dissertation are absolute distances and
relative changes between the states are expected to be less because the source of
error, the orientation factor, is not likely to change among states.
The distance changes for the histag-∆N*-AMPA-S653C receptor reflecting
cleft closure (4 Å) upon the addition of glutamate are similar to those seen in the
isolated LBD of 5 Å, clearly indicating that the modified AMPA receptor in the
presence of transmembrane segments experiences cleft closure conformational
changes like those seen in the isolated LBD. The absolute distances obtained from
the LRET investigations of the functional receptor cannot not be directly compared
to that of the isolated LBD LRET distances since the soluble protein used in the
LRET investigations was in the GluR2 background with a thrombin digestion site
and not the TAGZyme site as in the functional receptor, thus trends are identified.
The crystal structure of the isolated GluR2-LBD reveals a cleft closure
conformational change of 6 Å upon glutamate binding, where the distance
measured is between site S652 and the N-terminus [56]. This distance is similar to
the LRET distances obtained from the soluble protein, although the distance
measured includes the hexahistidine tag. Moreover, the kainate-bound state cleft
closure distance obtained from the histag-∆N*-AMPA-S653C receptor follows the
trend of intermediary distances between apo and glutamate bound receptor as
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observed in the isolated GluR2-LBD crystal structure. These results indicate that
this LRET based probe can clearly differentiate between the extents of cleft closure
and provide another clue that the isolated LBD is a good model for the full receptor
to study activation. Additionally, the hypothesis for activation holds true, where
structural information from a functional receptor coupled with functional data from
the full receptor suggest that the extent of cleft closure correlates with the extent of
activation [96].
Moreover, the results with the AMPA receptors as well as the soluble ligand
binding domain of the receptor establish the modified LRET method of using a
polyhistidine tag with the Ni-NTA based fluorophore for LRET investigations of small
distance changes without the requirement for purification. This methodology can be
extended to any protein in which a polyhistidine tag can be introduced with no effect
on the function. Furthermore, the method of inserting a protease recognition site
between the donor and acceptor fluorophore to accurately determine the specific
FRET/LRET is not limited to the histidine tag-cysteine pair but can be universally
applied to any FRET/LRET investigations with any donor-acceptor sites (Figure 27)
[96].
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Figure 27 Modifed FRET/LRET as a molecular ruler. The modified method allows
the determination of the FRET/LRET signal between a donor and acceptor
fluorophore by quantitatively determining the non-specific background FRET/LRET.
A protease recognition or stop site between the acceptor site and the protein of
interest is introduced. This allows the fluorophore to be cleaved off, thus removing
the acceptor site for FRET/LRET experiments [96].
Reproduced in part with permission from Gonzalez, J., Rambhadran, A., Du, M.,
Jayaraman, V. 2008. LRET investigations of conformational changes in the ligand
binding domain of a functional AMPA receptor. Biochemistry 47:10027-10032.
Copyright 2008 American Chemical Society.
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IV. Future experiments
Does this hypothesis for activation hold true in an even more physiological
state, in the presence of regulatory proteins that co-assemble with the AMPA
receptors? The transmembrane AMPA receptor regulatory protein (TARP) family
consists of several proteins that alter AMPA receptor function. Stargazin, a member
of the TARP family, was first studied in the stargazer mouse, which displays an
unsteady gait and has absence epilepsy.

These mice were later found to be

deficient in functional AMPA receptor expression in the cerebellar granule cells
[106, 107]. Stargazin is a 38 kD membrane protein containing four transmembrane
segments, an extracellular domain, and an intracellular domain (Figure 28). It has
previously been shown that the intracellular C-terminal domain is required for AMPA
receptor trafficking and the first large loop in the extracellular domain alters AMPA
receptor biophysical properties [106, 108-116]. Enhanced trafficking of the AMPA
receptor increases the total currents elicited, and whole-cell current measurements
show that stargazin slows glutamate-mediated AMPA receptor deactivation and
desensitization [106, 110].

At the single channel level, stargazin increases the

channel opening to the large conductance states and increases the bursting activity
of single channels, similar to that of inherent AMPA receptor activity found in
neurons [110]. Interestingly, the presence of stargazin increases the efficacy of the
partial agonist kainate [116]. In regards to the current hypothesis for activation, does
an increase in kainate efficacy suggest that stargazin's interactions with the LBD
enhance kainate-induced cleft closure? This question can be answered with the
modified LRET technique used to measure AMPA receptor cleft closure
104

conformational changes in the presence of stargazin, and test the hypothesis for
activation in a functional receptor in a physiologically relevant state.
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Figure 28 Detailed schematic of stargazin topology.

Stargazin contains an

intracellular N-terminus, four transmembrane segments, an extracellular domain,
and an intracellular C-terminal domain.
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Chapter 5—LRET Part II: Dimer Interface Rearrangement in a Functional
AMPA Receptor

108

I. Testing the desensitization hypothesis
Currently, no direct structural information exists for a functional AMPA
receptor in the desensitized state. As previously mentioned, it is hypothesized that
glutamate binding to the bi-lobed ligand binding domain causes cleft closure, which
pulls apart the transmembrane segments causing the channel to open. At prolonged
times, the receptor desensitizes; the stress on the transmembrane segments
causes the decoupling of the dimer interface resulting in the channel closure [61].
The hypothesis for desensitization is based on indirect structural information
from isolated LBD crystal structures that showed cyclothiazide, an allosteric
modulator, and mutations in the dimer interface, such as L483Y, that stabilize the
dimer interface block the entrance to the desensitized state. Based on the crystal
structures, it is expected that desensitization will increase the intersubunit distance
between domain 1 due to the decoupling of the dimer interface [61, 72-74]. This
conformational change is well reflected at residue S741 where the crystallographic
intersubunit distance reveals a coupled dimer interface in the resting and open state
of the receptor as shown in Figure 29 A and C, respectively.

Two possible

desensitized state structures of the isolated LBD are available including glutamatebound structure with a coupled dimer interface (Figure 29 B) and glutamate-bound
GluR2-S729C with an artificially decoupled dimer interface (Figure 29 D). It has not
been shown directly which structure is an accurate representation of the
desensitized state.
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Figure 29 AMPA receptor isolated LBD (GluR2-S1S2) crystal structure highlighting
dimer interface conformational changes.

The structures are shown in the (A)

resting state, (B) glutamate-bound state, (C) glutamate-bound state in with
cyclothiazide bound (open state), and (D) artificially decoupled desensitized state
with the S729C mutation present [56, 58, 74]. The residue at position 740 (741 in
GluR4) reflects dimer interface conformational changes and is represented as
spheres. The linker region that represents changes at the channel is in magenta.
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Functional studies of the desensitized state by electrophysiology have been
performed on the full receptor to elucidate structural changes at the dimer interface;
however, the resting state does not exhibit currents and thus cannot be studied by
this method [58]. The crystal structure of the full receptor was obtained in the
presence of the competitive antagonist, ZK 200775 [62]. The antagonist-bound
form shows a cleft that is more open than the resting, apo state and shows a
coupled dimer interface. It is currently not known whether the antagonist-bound
form of the full receptor is an accurate representation of the apo, resting state.
II. Establishing LRET to study intersubunit distances
a. LRET labeling strategy
Chapter 5 aims to examine the current desensitization hypothesis by using a
modified LRET technique to directly measure the intersubunit distance change.
Additionally, the resting state of the receptor has also been studied and compared
to the activated state, the desensitized state, and in the presence of ZK 200775.
These investigations are performed using functional AMPA receptors expressed in

Xenopus oocytes and Human Embryonic Kidney-293 (HEK-293) cells. ∆N*-AMPA
receptors, as discussed in the previous chapter serve as the background, control
construct for the LRET studies, where the N-terminal domain and 2 extracellular
cysteines have been removed. Cysteines were introduced at sites G740C, S741C,
or S742 to produce three probes that reflect dimer interface conformational
changes. Each modified receptor was tagged with maleimide derivatives of donor
and acceptor fluorophores, as depicted in Figure 30. A 1:4 ratio of the ATTO465
(acceptor) to terbium chelate (donor) were used to tag the receptor; this type of
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labeling strategy has been successfully performed in the study of intersubunit
distances in potassium channels [83].

These fluorophores label the cysteines

introduced in each of the subunits of the tetramer, and the labeling ratio makes
certain that a large number of receptors contain at least one acceptor. The donor
only or acceptor only labeled receptor will not contribute to sensitized emission
measured at 510 nm, as there are no donor:acceptor pairs in these receptors
(Figure 31 A). The acceptor fluorophore was further characterized by assessing
ATTO465-maleimide absorption in the presence of glutamate and cyclothiazide
(Figure 31 B). No significant changes were identified, thus the addition of agonist
and modulator does not perturb the fluorophore’s environment. Although the 1:4
ratio labeling strategy limits accurate measure of absolute distances, it does not
significantly impact the changes in distances measured using the same protein
sample, as will be performed in this investigation. The intersubunit distance will be
measured by studying the LRET lifetimes, and changes in the distance in the
resting (apo) state, glutamate-bound (desensitized), glutamate-bound in the
presence of cyclothiazide or the L483Y mutation (open), and in the presence of
competitive antagonist, ZK 200775, will reveal the conformational changes at the
dimer interface.
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Figure 30 The modified GluR4 subunit of the AMPA receptor for LRET
investigations. In this protein the N-terminal domain (22-402 amino acids) has been
deleted, two cysteines at site 426 and 529 replaced with serines, and a cysteine
introduced at site G740, S741, or S742. The modified receptor is tagged with
maleimide derivatives of ATTO465 and a terbium chelate through a thiol linkage at
the cysteine sites.
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Figure 31 Fluorophore control experiments. (A) To assess background LRET
signal, donor only fluorophore (black) and acceptor only fluorophore (red) samples
were studied at 510 nm, the wavelength of sensitized emission. (B) Absorption of
ATTO465-maleimide (acceptor) was measured (black).

The addition of 10 mM

glutamate (green) and 100 µM cyclothiazide (red) did not perturb the absorption
spectrum.

116

0.0010

Fluorescence

A

0.0005
0.0000
-0.0005
-0.0010

2,000

1,000

Time (µs)

B

0.04

Absorbance

0.03

0.02

0.01

0.00
375

400

425

450

Wavelength (nm)

117

475

500

b. Receptor characterization by electrophysiology
Each of the mutant proteins were expressed in either oocytes or HEK-293
cells and characterized by electrophysiological investigations to ensure that the
labeled, modified receptors exhibit similar functional properties as the wild-type
receptor (Figure 32).

The two well-established membrane protein expression

systems were utilized to show that the LRET data obtained was not system specific.
Dose response curves were obtained by studying the normalized maximum current
measured by two-electrode voltage clamp (oocytes) or whole-cell recordings (HEK293 cells) at various concentrations of glutamate. Mutants receptors, ∆N*-GluR4G740C,

∆N*-GluR4-S741C, and

∆N*-GluR4-S742C,

expressed

in

oocytes

displayed similar dose response curves to the control, ∆N*-GluR4 receptors.
Mutant receptors (∆N*-GluR4-Th-S741C-Th) expressed in HEK-293 cells also had
a similar dose response curve to the wild type GluR4-flip receptors.
For AMPA receptor expression in oocytes, in order to reduce non-specific
labeling, the cysteine blocking procedure with β-maleimidopropionic acid was
implemented [83, 96]. For the 1:4 labeling ratio, 0.5 µM ATTO465 (acceptor) and 2
µM terbium chelate (donor) was added to oocytes in storage solution and incubated
for one hour at 18 °C. The excess fluorophore was removed from the oocytes with
gentle rinsing with storage solution.

Membranes from 300 oocytes expressing

mutant receptors were prepared for LRET studies and other electrophysiological
investigations.

In Figure 33, single channel recordings were performed on

membranes reconstituted into bilayers in order to establish if the manipulations
during tagging the receptor and membrane preparations alter the function of the
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Figure 32 Dose response curves for mutant and wild-type AMPA receptors. (A)
Normalized glutamate-evoked currents from ∆N-GluR4 receptors (red), ∆N*-GluR4G740C (blue), ∆N*-GluR4-S741C (green), ∆N*-GluR4-S742C (black) receptors
expressed in oocytes were plotted as a function of glutamate concentration. (B)
Mutant ∆N*-GluR4-Th-S741C-Th receptors (black) and Wild type GluR4-flip
receptors (red) expressed in HEK-293 cells were studied. Currents elicited by
various concentrations of glutamate were normalized to currents evoked by 10 mM
glutamate in the presence of saturating concentrations of cyclothiazide to block
desensitization.

119

B
Normalized Currents

Normalized Currents

A
1.0
0.8
0.6
0.4
0.2
0.0

1.0
0.8
0.6
0.4
0.2
0.0

0.01

0.1

1

10

0.01

Glutamate (mM)

0.1

1

Glutamate (mM)

120

10

Figure 33 Single channel recordings performed on membrane preparations of
labeled, mutant receptors reconstituted in lipid bilayers (A) Single channel traces
were analyzed to produce amplitude histograms for fluorophore tagged ∆N*-GluR4S741C receptors. The voltage was held at 120 mV and recordings were measured
at 1 mM Glutamate in the presence of 100 µM cyclothiazide. The major
conductance state is found to be at 9-12 pS. Time distributions for two separate (B)
open times and (C) close times for tagged ∆N*-GluR4-S741C.
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receptor. The recordings were performed by our collaborator at Auburn University
in Alabama and determined that mutated receptors (tagged with fluorophores)
exhibit similar single channel open probability and conductance to the wild-type
receptor suggesting that the manipulations for the LRET do not have a significant
effect on the receptor function. Additionally, for the LRET control experiments, nonAMPA receptor expressing oocytes (non-injected) were prepared and studied in
parallel in order to subtract remaining background LRET.
For AMPA expression in HEK-293 cells, the ∆N*-GluR4-S741C construct
used for oocyte expression has been further modified. For HEK-293 cells, preblocking inherent cysteines with β-maleimidopropionic acid is not effective. In order
to address non-specific background LRET in this expression system, a thrombin
cleavage site (LVPRGS) was introduced on each side of the S741C mutation to
create the ∆N*-GluR4-Th-S741C-Th receptor. A 1:4 labeling ratio of donor to
acceptor in phosphate buffered saline (PBS) is added to cells expressing the
receptor and incubated for one hour at room temperature. Excess fluorophores are
removed by washing with PBS, and intact cells resuspended in PBS are used for
LRET investigations. The LRET signal measured after the addition of thrombin and
cleavage of the S741C provides a quantitative measure of the background nonspecific LRET, which can be removed from the initial signal obtained prior to the
addition of the protease to obtain the LRET signal of interest (Figure 34).

For

thrombin cleavage of the cysteine at position S741, 3 U of thrombin are added to
the sample of HEK-293 cells used previously for initial LRET studies; the cells are
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Figure 34 Representative non-specific, background LRET for ∆N*-GluR4-Th-S741Th receptors expressed in HEK-293 cells. For the resting state, the initial LRET
signal (before thrombin cleavage) and the non-specific, background LRET signal
(after thrombin cleavage) were obtained at 510 nm for tagged receptors.
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incubated for three hours at room temperature.
Furthermore, the modified receptors were further tested by electrophysiology
to ensure that each state of the receptor is entered upon the addition of agonist,
modulator, or the introduction of mutations, simulating LRET experiments In Figure
35, representative macroscopic currents obtained by two-electrode voltage clamp
(oocytes) and whole-cell recordings (HEK-293 cells) are shown. In Figure 35 A,
currents from ∆N*-GluR4-L484Y-S741C receptors were measured in the presence
of saturating concentrations of glutamate and cyclothiazide to reproduce conditions
for the open state. In the presence of glutamate alone and in the presence of
glutamate plus cyclothiazide, the desensitized state is not entered. Additionally, in
the unligated, apo state, the presence of the L484Y mutation in the absence of
glutamate does not evoke currents. In Figure 35 B, for ∆N*-GluR4-Th-S741C-Th
expressed in HEK-293 cells, no currents were obtained in the absence of ligand to
obtain the apo, resting state. Saturating concentrations of glutamate (10mM) were
added to show that the receptor enters the desensitized state. The open state is
obtained in the presence of glutamate and 100 µM cyclothiazide. Additionally, in
the presence of the L484Y mutation, desensitization is blocked. Hence, it is clear
that the modified receptors are capable of entering various states of the receptor
under the conditions for LRET investigations. For the LRET investigations, the
lifetimes are used to calculate the average distance between with donor and
acceptor fluorophore in conditions for the receptor to enter the resting, open, and
desensitized state.
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Figure 35 Current traces from modified receptor subjected to LRET conditions to
obtain various states of the receptor.

(A) Currents elicited by saturating

concentrations of glutamate (10 mM) and in the presence and absence of
cyclothiazide (100 µM) were recorded by two-electrode voltage clamp from ∆N*GluR4-L484Y-S742C receptors expressed in oocytes. (B) Currents elicited by
saturating concentrations of glutamate (10 mM), in the presence glutamate plus
cyclothiazide (100 µM), and for the L484Y mutant were recorded by whole-cell
recordings from ∆N*-GluR4-Th-S741C-Th receptors expressed in HEK-293 cells.
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III. LRET Results and Discussion
a. Intersubunit distance measurements for the states of the receptor
By studying the LRET lifetimes in the unligated, glutamate-bound, and
glutamate-bound in the presence of cyclothiazide or the L483Y mutation will reveal
the conformational changes at the dimer interface in the apo, desensitized, and
open states, respectively. The LRET signal measured for fluorophore tagged noninjected, control oocytes or after thrombin cleavage of receptors expressed in HEK293 cells provides a direct quantification of the background non-specific LRET,
which can be removed from the initial signal to provide the specific LRET signal as
shown in Figure 36-37. Figure 38 reveals that LRET lifetimes recorded from donoronly tagged ∆N*-AMPA-S741C receptors at 488 nm does not significantly change
among the various states of the receptor, suggesting that changes in sensitized
emission lifetimes are significant.
The sensitized emission lifetimes obtained could be well-represented by a
two exponential decay for donor:acceptor labeled ∆N*-GluR4-G740C, ∆N*-GluR4S741C, and ∆N*-GluR4-S742C expressed in oocytes and ∆N*-GluR4-Th-S741C-Th
expressed in HEK-293 cells. The faster lifetime and hence shorter distance makes
up the majority of the LRET signal obtained (90%), and these shorter distances are
similar to those observed in the crystal structures (Table 2).

For example, the

shorter distance obtained in the open state (represented by the presence of the
L484Y mutation with saturating concentrations of glutamate and cyclothiazide) are
20±0.5 Å at position 740, 19±0.6 Å (22±0.2 Å in HEK-293 cells) at position 741, and
21±0.3 Å at position 742, which are similar to nitrogen backbone crystallographic
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Figure 36 Sensitized emission measured at 510 nm for donor:acceptor tagged
receptors expressed in oocytes.

LRET lifetimes for (A) ∆N*-GluR4-G740C, (B)

∆N*-GluR4- S741C, (C) ∆N*-GluR4- S742C, (D) ∆N*-GluR4-L484Y-G740C, (E)
∆N*-GluR4-L484Y-S741C, and (F) ∆N*-GluR4-L484Y-S742C receptors in the
unligated state (black), with 10 mM glutamate (green), and with 10 mM glutamate
plus 100 µM cyclothiazide (red).
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Figure 37 Specific LRET signal obtained after background subtraction for
donor:acceptor tagged receptors expressed in HEK-293 cells.

LRET signal

obtained in the unligated state (black), with 10 mM glutamate (green), with 10 mM
glutamate plus 100 µM cyclothiazide (red), and in the presence of 200 nM
antagonist ZK 200775 (blue) for (A) ∆N*-GluR4-Th-S741-Th and (B) ∆N*-GluR4L484Y-Th-S741-Th receptors.
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Figure 38 Sensitized emission measured at 488 nm for donor-only labeled ∆N*GluR4-S741 receptors expressed in oocytes. LRET lifetimes were obtained in the
apo (black), open (10 mM glutamate plus 100 µM cyclothiazide-red), and
desensitized (10 mM glutamate-green) states.
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Table 2 LRET lifetimes and calculated intersubunit distances. Lifetimes of the
donor-only labeled protein and the subtracted lifetimes for the sensitized emission
of the acceptor in the presence of the donor with the corresponding distances for
the apo/resting state, the open channel state, and the desensitized state.
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Protein

Ligand/State

Donor
lifetime
(µs)

∆N*-GluR4-G740C

Apo/resting

1526±50

∆N*-GluR4-G740C

∆N*-GluR4-G740C

Glu/desensitized

Glu+CTZ/open

∆N*-GluR4-G740CL484Y

Apo

∆N*-GluR4-G740CL484Y

Glu

∆N*-GluR4-G740CL484Y

Glu+CTZ/open

∆N*-GluR4-S741C

Apo/resting

∆N*-GluR4-S741C

∆N*-GluR4-S741C

Sensitized
emission
lifetime
(µs)

Distance
(Ǻ)

188±12

25±0.3

535±15

32±0.3

173±10

25±0.3

534±18

32±0.3

73±10

21±0.5

439±15

30±0.3

63±5

20±0.3

336±18

27±0.3

67±3

20±0.2

357±20

28±0.3

61±8

20±0.5

444±21

29±0.3

132±9

23±0.3

595±23

32±0.3

126±10

23±0.3

522±20

31±0.3

60±7

20±0.4

367±15

29±0.3

53±9

19±0.6

542±19

30±0.3

55±10

20±0.6

565±17

31±0.3

51±10

19±0.6

584±15

31±0.3

1510±45

1534±45

1841±50

1845±60

1845±60

1682±50

Glu/desensitized

Glu+CTZ/open

∆N*-GluR4-S741CL484Y

Apo

∆N*-GluR4-S741CL484Y

Glu

∆N*-GluR4-S741CL484Y

Glu+CTZ/open

1686±60

1612±60

1877±45

1820±45
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1818±50

∆N*-GluR4-ThS741C-Th

Apo/resting

∆N*-GluR4-ThS741C-Th

Glu/desensitized

∆N*-GluR4-ThS741C-Th

Glu+CTZ/open

∆N*-GluR4-ThS741C-Th

ZK200775

∆N*-GluR4-ThS741C-Th-L484Y

Apo

∆N*-GluR4-ThS741C-Th-L484Y

Glu

∆N*-GluR4-ThS741C-Th-L484Y

Glu+CTZ/open

∆N*-GluR4-S742C

Apo/resting

∆N*-GluR4-S742C

∆N*-GluR4-S742C

188±13

25±0.3

535±16

31±0.3

174±4

25±0.2

534±20

32±0.3

73±3

21±0.2

439±15

30±0.3

77±5

21±0.2

489±15

30±0.3

92±3

22±0.2

502±15

31±0.3

70±3

21±0.2

504±15

31±0.3

92±3

22±0.2

572±20

32±0.3

124±7

23±0.3

596±22

32±0.4

118±6

23±0.2

517±15

30±0.3

62±5

20±0.3

444±15

29±0.3

66±5

21±0.3

464±15

30±0.3

67±5

21±0.3

477±15

31±0.3

64±5

21±0.3

446±15

30±0.3

1578±45

1505±45

1579±55

1679±45

1609±60

1565±55

1579±50

1704±60

Glu/desensitized

Glu+CTZ/open

∆N*-GluR4-S742CL484Y

Apo

∆N*-GluR4-S742CL484Y

Glu

∆N*-GluR4-S742CL484Y

Glu+CTZ/open

1730±60

1682±55

1557±45

1517±45
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distances measured at these sites, 17 Å, 20 Å, and 22 Å, respectively. The full
receptor crystal structure suggests that distances between these sites across the
dimer vary from 55 to 70 Å, well outside the preferred efficiency range for the
fluorophore pair chosen (R0=35 Å) [62]. The 10% of the lifetime observed are in the
range of 30 to 32 Å, and hence can be attributed to the distances across the dimer.
The longer distances may be due to a small fraction of the receptors in a different
state or residual, non-specific signal.
The shorter distances that correspond to distances within the dimer show
that the open channel state undergoes an increase distance change of around 3 to
5 Å upon desensitization of the receptor (glutamate-bound). This conformational
change coincides with the current hypothesis for desensitization where the dimer
interface is coupled in the open state and upon entrance into the desensitized state,
the interface rearranges and decouples [61]. Additionally, the GluR2-S729C isolated
LBD crystal structure shows a greater distance change (8 Å) from the open to
desensitized state at site 740 (741 in GluR4) [58]; because this structure has been
acquired by artificially decoupling the dimer interface, this could lead to a more
decoupled state than what is observed in a physiologically relevant state. It should
be noted that the LRET distances observed are representative of the on average
distances that the dynamic receptor enters during a given state.
b. Mechanism for the resting, activated, and desensitized states
LRET lifetimes were also obtained for the apo, resting state of the receptor
(in the absence of the L484Y mutation), for which no direct structural data exists.
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Moreover, the intersubunit distances obtained in the apo state for each of the
probes is not consistent with the current hypothesis; the expected crystallographic
distance for the apo state shows that the interface is coupled at 16 Å much like that
of the open state. The LRET intersubunit distances, however, reveal that the apo
state is 3 to 5 Å longer than the distances measured for the open state (Table 2). In
fact, the apo state resembles that of the desensitized state where the dimer
interface is decoupled, and hence the dimer interface is not pre-formed as
suggested by the isolated LBD crystal structure. This also suggests that in the
absence of transmembrane segments, the isolated LBD has a propensity to
crystallize as a dimer that is coupled no matter what state the receptor is in.
Additionally, detailed GluR2-S729C crosslinking experiments revealed that the
dimer interface is dynamic by showing that the disulfide bond is not formed within
the interface when the L484Y mutation is present; however, it is formed in both the
resting and desensitized state and the presence of antagonist reduced disulfide
formation [117]. Thus, stabilization of the dimer interface by L484Y blocked the
formation of the disulfide, and the formation of the disulfide in the unligated, resting
state suggest that dimer interface contacts were broken.
The crosslinking studies as well as the crystal structure of the isolated LBD
L483Y (L484Y in GluR4) mutant suggest that the dimer interface is stabilized [61,
117].

LRET distances obtained from the L484Y mutants are similar in the apo

state, in the presence of glutamate, and in the presence of glutamate plus
cyclothiazide suggesting that the dimer interface is coupled. The LRET distances
for each of the L484Y probes resemble the LRET distances in the open state
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(glutamate in the presence of cyclothiazide). This data supports the notion that the
dimer interface is pre-formed and hence stabilized in the L484Y mutant. As shown
in the electrophysiological characterization of the L484Y modified receptors,
glutamate is required to activate the channel; no currents in this mutant were
elicited in the absence of agonist (Figure 35). A pre-form dimer would, on the other
hand, aid in the energetics of the conformational changes associated with the
activation of the receptor, as shown by a decreased EC50 compared to wild-type
receptors.
The LRET distances thus far have been compared to crystallographic
distances measured in the well-characterized isolated LBD dimer; however, these
structures are limited by the lack of the transmembrane segments, the functional
portion of the receptor. With the recently solved structure of the full receptor, LRET
distances can now be compared to a more relevant structure. GluAcryst was solved
with ZK 200775 bound resulting in an elongated cleft distance; the structure showed
a coupled dimer interface measuring around 20 Å [62] . Thus, LRET distances were
obtained for ∆N*-GluR4-Th-S741C-Th receptors in the presence of the competitive
antagonist (Figure 37). The measured LRET distance of 21±0.2 Å would suggest
that the dimer interface is coupled like the open state as detected by LRET and is
similar to the antagonist-bound full receptor structure.

Together, these results

support that the dimer interface is dynamic, and the resting state of the receptor
primarily exhibits a decoupled dimer interface.
With the insight from the LRET intersubunit measurements of the dimer
interface, a mechanism is proposed that differs from the mechanism based on
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crystallographic measurements (Figure 39). The LRET investigations suggest that
in the apo/resting state, the channel is closed, the cleft is open, and dimer interface
is decoupled. Upon ligand binding to the ligand binding domain, the cleft closes by
domain 2 moving up towards domain 1. Contacts form between the dimer interface
at domain 1 to transiently stabilize the open channel. Cleft closure pulls apart the
transmembrane segments causing the channel to open (activation) and stress on
the transmembrane segments causes the decoupling of the dimer interface
resulting in the channel closure (desensitization).

IV. Future directions
Dimer interface rearrangement has proven to play an important role in all
states of the AMPA receptor. As posed earlier during the activation studies, how
would the conformational changes seen in the functional receptor behave in an
even more physiologically relevant environment? Stargazin, known to alter AMPA
receptor biophysical properties [109-111, 113-116], could act similarly to the L484Y
mutation by stabilizing the dimer interface thereby enhancing receptor activation.
Additionally, the dimer interface is also being investigated in other glutamate
receptor subtypes; however, no in depth structural information exists. Receptor
modulators including Zn2+ and protons have been shown to bind to the N-terminal
domain and consequently alter activation and desensitization at the dimer interface
[118-120]. Similar LRET studies could be performed in order to test the state of the
interface in the presence of modulators.
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Furthermore, studies show that the R629E, a mutation outside the ligand
binding domain, blocks desensitization [76]. Hence, there is currently no structural
evidence for this mutant. For the proposed experiments the intersubunit distance
will be determined by FRET using the G740C, S741C, and S742C. The same
protocol as mentioned above will be used in the FRET measurements where a 1:4
ratio of acceptor and donor will be used to label the mutant protein. The only
difference is that the current experiments will be performed in the context of the
R629E mutation. This mutation will provide insight into desensitization by
determining the intersubunit distances in different states of the receptor. From our
studies, if there is no change in the intersubunit distance between the apo and
glutamate bound forms in the R629E mutation, it would suggest that the mutation
allosterically stabilizes the domain 1 interface. However, if the intersubunit distance
increases upon going from the apo to the glutamate bound form, then it would
suggest that dimer decoupling occurs but is not communicated to the channel
segments due to the R629E mutation, and that the R629E mutation stabilizes the
open channel form by stabilizing near the channel. These studies might reveal
another level by which desensitization is controlled and call for further investigation.

143

Figure 39 Proposed mechanism for the resting, open, and desensitized state based
on LRET investigations. In the resting state, no ligand is bound and the cleft is
open. Upon ligand binding, the cleft closes and pulls apart the transmembrane
segments thereby opening the channel. Contacts form between the dimer interface
to transiently stabilize the open channel. Stress on the linker to the transmembrane
segments causes the decoupling of the dimer interface resulting in a closed
channel, the desensitized state.
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Chapter 6—LRET Part III: Ca2+ subdomain orientation of Na+/Ca2+ exchangers
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I. Na+/Ca2+ exchanger Structure and Function
In previous chapters, I have established LRET as a powerful tool capable of
measuring conformations within a protein in a dynamic state. This chapter of the
dissertation discusses a collaborative project with Dr. Lei Zheng and his postdoctoral fellow Mousheng Wu (UT-Houston Medical School), where LRET
measurements are performed on the Ca2+ regulatory domain of the Na+/Ca2+
exchanger in order to support its crystal structure solved by his lab. Na+/Ca2+
exchangers (NCX) play a critical role in Ca2+ homeostasis throughout the
mammalian system, a process vital for cardiac contractibility in addition to
excitation/relaxation coupling in the brain [121, 122]. These highly regulated antiporter proteins enable the exchange of Na+ and Ca2+ (3 Na+:1 Ca2+) ions across the
plasma membrane depending on the membrane potential and chemical gradient of
the ions [123]. In order to understand the function of the Na+/Ca2+ exchanger,
detailed investigations of the structure of the protein are required.
Na+/Ca2+

exchangers

are

a

family

of

proteins

that

contain

nine

transmembrane segments including a Ca2+ regulation domain, a large intracellular
loop (~500 amino acid residues) flanked by the fifth and sixth transmembrane
segments. The domain consists of two subdomains, CBD1 and CBD2, which serve
as Ca2+ sensors [124]. Although CBD1 is conserved throughout the family,
alternative splicing of CBD2 enables further fine tuning of Ca2+ regulation (Wu).
The structures of individual Ca2+ sensors, CBD1 and CBD2 from canine exchanger
NCX1 and Drosophila exchanger CALX, were solved by NMR and x-ray
crystallography [125-129]. It has been shown that upon Ca2+ interaction,
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conformational changes are induced within the CBD domains and each is capable
of Ca2+ interaction, however, Ca2+ binding to an individual domain does not induce
large scale conformational changes [128, 130, 131]. No structural information for
the complete CBD domain is available; however, it has been shown by mutagenesis
that interaction between the domains is required for function [132, 133]. It is
currently hypothesized that Ca2+ binding induces a conformational change within the
CBD domain and this is translated to the adjacent transmembrane segments such
that the ion exchange pore opens/closes. Nevertheless, the mechanism for Ca2+
conductivity by Ca2+ binding is not completely clear without the full structure of the
CBD domain. Additionally, it is not understood how the varied residues in CBD2
introduced by alternative splicing alters NCX Ca2+ regulation, as shown in isoforms,
CALX1.1 and CALX1.2.

Each isoform clearly demonstrates drastically different

Ca2+ regulation properties [134].

In order to elucidate the mechanism for Ca2+

regulation, Wu determined crystal structures of complete NCX Ca2+ regulatory
domain of two splice variants, CALX1.1 and CALX1.2, in the apo form.

II. LRET Results and Discussion
The crystal structures of the CBD domain revealed an open V-shape of
CBD1 and CBD2. Additionally, Ca2+ binding sites of CBD1 were determined to be
located at the hinge region. As shown in Figure 40 A, three cysteine mutations
were introduced at various positions (S581, T560, T567) on the CBD2 of the
CALX1.1 isoform which contained an N-terminus histidine tag. These probes allow
the measurements of the conformation of the CALX1.1 isoform in its open state in
order to support the structure solved by Wu. LRET measurements were performed
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between the introduced cysteine mutant and the N-terminus his-tag labeled with
terbium chelate and (Ni-NTA)2Cy3, respectively.

LRET lifetimes were obtained

(Figure 40 B-C) and distances were calculated (Table 3). These measurements
demonstrate that the distance from the histag (N-terminus) to T567C, the cysteine
farthest from the hinge region, is significantly longer (56±5 Å) than to those closer to
the hinge region. LRET distances for T560C and S581C are shorter at distances of
41±2 Å and 42±2 Å. These studies reveal that the open V-shape conformation
observed in the crystal structures exists in solution without crystallographic
contraints.
Wu solved the crystal structure of both isoforms, CALX1.1 and CALX1.2, and
the conformational comparison between isoforms reveals that the orientation angle
of the open V-shape is different. CALX1.1 exhibits a strong response to regulatory
Ca2+, dissimilar to the regulatory Ca2+ independence of CALX1.2 [134]. Hence, the
difference in orientation angles observed in the crystal structures suggest that the
orientation angle of the CBD subdomain is the primary means for Ca2+ mediated
NCX regulation. Therefore, Wu proposed that CALX Ca2+ regulation occurs by Ca2+
binding at CBD1 thus stabilizing the subdomain interaction between CDB1 and
CBD2. This interaction changes the orientation angle between CBD1 and CBD2,
and consequently repositions the transmembrane segments close the ion
translocation pathway. Despite various members of the family (NCX1 and CALX)
displaying opposite Ca2+ regulation properties, they have conserved hinge regions.
Wu suggests that the altered orientation angle established by the crystal structures
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of the splice variants of CALX may represent a common structural feature of the
NCX family exhibited for Ca2+ mediated NCX regulation.
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Figure 40 LRET measurements in the Ca2+ regulatory domain of CALX1.1. (A)
Representation of the donor and receptor positions in LRET measurements.
Acceptor Cy3 was coordinated with the histag at N-terminus of the Ca2+ regulatory
domain of CALX1.1 spaced with a thrombin cleavage sequence. (B) Donor-only life
collected at 545 nm. (C) The LRET lifetimes as measured by the sensitized
emission of the acceptor at 575 nm for the mutant proteins containing an N-terminal
histag and cysteines located at positions 581 (red), 560 (blue), and 567 (black) on
CBD2.
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Table 3 LRET lifetimes and distances between N-terminus His tag to different
positions on CBD2. Crystallographic distances are measured between the Cα
atoms between the N-terminal I422 and respective donor residue.
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Position

Donor
lifetime
(µs)

Sensitized
emission
lifetime (µs)

Distance to Histag (LRET) (Å)

Distance to N
terminus 422 (in
structure) (Å)

581

1607±55

81±2

42±2

44

560

1607±69

77±4

41±2

53

567

1612±38

380±32

56±5

70
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Chapter 7-Overall Conclusions
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Neurons communicate with each other by chemical signals and transmit
information by electrical signals. An abundant protein in the brain known as a
glutamate receptor is a key player in this process by converting chemical signals
into electrical signals. The glutamate receptor is a ligand-gate ion channel, and its
unique three-dimensional structure resembling a cleft enables the protein to bind to
glutamate (chemical signal), and in consequence this interaction allows the receptor
to open its pore and act as a gateway to allow charged ions (electrical signal) to
pass through, hence sending the message to the next neuron [17-21].

Thus,

glutamate receptors, a model to study allosterism, couple ligand binding to receptor
function. So the question arises, how does a small molecule like glutamate induce
allosteric changes in glutamate receptors and in turn dictate function? Recently, the
structure of the full receptor was solved [62]; however, these structures are not
dynamic representations of the receptors in a physiologically relevant state.

The

approach in this dissertation includes biophysical techniques that can measure the
conformational changes in the structure of a functional, ligand-bound receptor and
directly correlate this structural data with the function of the receptor, as probed by
the electrical signal produced by the receptor.
To reiterate the importance of the mechanism based on LRET distances, I
return to the subject of the allosteric behavior of AMPA receptors and its
implications for other subtypes of glutamate receptors. As discussed in Chapter 1,
Jin et al. studies suggest that AMPA receptors are allosteric proteins that closely
follow the multi-state induced fit, KNF model. Jin et al. provided an explanation for
agonist efficacy using the 5-substituted willardiines. These partial agonists showed
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a graded cleft closure, which is consistent with the KNF model. They showed how
partial agonists, at saturating concentrations, could induce submaximal currents and
cleft closure [59]. In addition, the extent of cleft closure as a result of the occluding
size of the substituent was correlated to the efficacy for activation of the receptor,
which also strongly supports the KNF model [18].

The degree of cleft closure

determines an individual subunits response the ligand binding and ultimately ion
channel opening. So, each subunit’s opening can then contribute to the opening of
higher subconductance states as it becomes more favored as the coupling
efficiency increases between ligand binding and activation of the channel [59].
The structural studies, however, were performed in the isolated ligand binding
domain, lacking the functional portion of the receptor. Additionally, because the
isolated LBD is dimeric, the cooperative structural changes between between the
domains is lacking.

To test the activation hypothesis in a functional receptor, I

measured the extent of cleft closure in the ∆N*-AMPA using a series of agonists
which exhibit a wide range of activations. In summary, the LRET experiments with
the modified receptor reveal that the distance change between the apo state and
glutamate-bound state, is in agreement with crystal structure distances, clearly
indicating that the modified, functional AMPA receptor undergoes similar graded
cleft closure conformational changes as seen in the crystal structures of the isolated
LBD.

The kainate-bound, partial agonist bound state showed an intermediate

distance compared to the difference between the apo and glutamate bound, full
agonist bound state as expected from the crystal structures.

The extent of

activation of the receptor shows a correlation to the extent of cleft closure induced
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by the agonist binding to the receptor. These results show that the isolated LBD is a
good model of the domain in the full receptor, thus the allosteric behavior
established by the isolated LBD studies can be extended to the functional receptor
[96]. It has been shown by LRET on isolated LBD of kainate receptors, that these
receptors exhibit a graded cleft closure [135]. However, the structure of the NMDA
receptor has not been extensively studied; these receptors are obligate heteromers
of glycine-binding NR1 or NR3 subunits and glutamate-binding NR2 [136-141].
NR1 isolated ligand binding domain structures reveal no changes in cleft closure
between full and partial agonists; and the NR2A isolated ligand binding domain has
only been solved in the presence of glutamate [139-141]. Thus, LRET studies could
be performed on NMDA receptors to determine if the NR2A subunit has graded cleft
closure.
The current hypothesis for desensitization is that the stress on the
transmembrane segments induced by cleft closure upon agonist binding results in
the separation of the interface (domain 1) between two subunits in the glutamate
receptor tetramer leading to desensitization [58]. This hypothesis is based on
indirect structural investigations and functional investigations of the isolated LBD
where the dimer interface is stabilized or destabilized. There is still no direct
structural evidence for this hypothesis. In order to obtain a more direct readout of
the conformational changes associated with these states, I have measured the
intersubunit distance in the apo and full agonist glutamate bound state of the protein
in the presence and absence of desensitization. Previous functional and structural
investigations using cyclothiazide and the L484Y mutation in AMPA receptors,
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which stabilize the dimer interface thus decreasing desensitization, as well as the
recent structure of isolated ligand binding domain of the S729C mutant, where the
protein is stabilized in the desensitized state and dimer interface is found to be
decoupled, have been used to describe the process of desensitization [56, 58, 74].
For studying intersubunit distances in the ligand binding domain of the AMPA
receptor, I modified the ∆N*-AMPA subunit to serve as a probe to reflect
intersubunit distance changes. These investigations suggest that the apo state of a
modified a functional AMPA receptor in the presence of the transmembrane
segments is decoupled, and during activation, the interface is coupled due to the
driving force of cleft closure, thereby stabilizing the open channel, and then the
interface decouples thus leading to desensitization.
The AMPA receptor studies were performed in functional receptors in the
absence of the NTD. Why are the LBD structural implications provided by the LRET
studies in the AMPA receptors important in NTD cleft closure studies in NMDA
receptors? The LBD as previously mentioned are connected to the NTD by linker
regions. Based on the functional investigations of NMDA receptors, it has been
hypothesized that non-competitive inhibitors such as Zn2+ and ifenprodil mediate
their effects by inducing a cleft closure of the NTD [118-120]. Additionally, the
allosteric coupling between the NTD and dimer interface at the LBD has also been
indirectly established by electrophysiological studies. It was found that when the
dimer interface is destabilized, there is an increase in Zn2+ inhibition, and the
reverse is true where stabilizing it decreases Zn2+ inhibition [118]. Thus, the LRETbased mechanism for AMPA receptors in addition to the fact that altering the dimer
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interface modulates the non-competitive inhibitors ability to inhibit the channel,
another molecular mechanism for NMDA and non-NMDA receptors is proposed
(Figure 41). Cleft closure in the LBD due to ligand binding leads to separation of
the linker regions to the transmembrane domain, opening the channel. Contacts at
the dimer interface of the LBD form to transiently stabilize to open state. Loss of
strain by the decoupling of the dimer interface results in channel closure. However,
in the presence of inhibitor, the NTD can undergo cleft closure conformational
change, and the linker region between the NTD and LBD separates. This results in
decoupling of the dimer interface of the LBD that in turn inhibits the channel. This
type of allosteric coupling can be tested using similar LRET investigations of the
NMDA receptor.
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Figure 41 Proposed mechanism for activation, desensitization and inhibition by
modulators. Agonist binding to the LBD induces cleft closure pulling apart the linker
to the transmembrane domain thus opening the channel (activation). The open
channel form is transiently stabilized by LBD dimer contacts. Stress on the linker
domain results in decoupling of the LBD dimer interface interactions leading to
channel closure (desensitization). Modulator binding to NTD causes cleft closure of
the NTD, which would lead to a separation of the linker region between NTD and
LBD, causing the decoupling of LBD dimer interface leading to channel closure
(inhibition). This inhibition is stabilized by dimer interactions at the NTD.
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The ultimate goal of this dissertation is to develop an understanding of how a
small molecule such as glutamate can bind to its receptor and cause a cascade of
events that alters the way neurons communicate with each other. This type of
regulation underlies complex brain activity like learning and memory. Hence, in
order to develop the next generation of drugs to treat neurological diseases
associated with excitotoxicity, such as Alzheimer's and Lou Gehrig’s disease [1730], further insight into how these receptors work is paramount.
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I. Molecular Biology
a. ∆N*-AMPA Receptor
Dr. Keinanen (University of Helsinki, Helsinki, Finland) provided the plasmid
for the GluR4-flip receptor with the N-terminal domain (residues 22-402) deleted. It
has been further modified by eliminating accessible cysteines by mutating two of the
accessible cysteines (C426, C529) on the extracellular side to serines, producing a
modified AMPA receptor. Cysteine mutations were introduced using the Stratagene
QuikChange site-directed mutagenesis kit (Stratagene, CA). The coding region was
sequenced in order to verify the integrity of the plasmid.
b Primers for mutagenesis
For cloning the cleft closure probe, histag-∆N*-AMPA-S653C, a cysteine was
introduced at site S653. Additionally, a hexahistidine tag was introduced at the Nterminus with a glutamine residue (P382Q) mutated between the histag and the
modified AMPA receptor sequence.
More specifically, the hexahistidine tag was inserted into the N-terminal
domain deleted GluR4 receptor after the viral signal peptide to replace the Nterminal flag epitope [45].

For introducing the hisidine tag, the forward primer

included a NheI restriction site, signal peptide, and a hexahistidine tag followed by
P382Q mutation:
GGCTAGCTATAAATATGACTATTCTCTGCTGGCTTGCGCTGTTGTCAACACTTA
CCGCCGTGAACGCACACCATCATCATCATCACCAGACTCTGGGCAATGAC.
The backward primer contained an EcoRI restriction site,
CGGAATTCTTTTGTTGACCCAGAATCAAGT.
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The PCR product was digested with NheI and EcoRI restriction enzymes,
and then cloned into the corresponding sites of the modified receptor [96].
For cloning modified receptors for the intersubunit distance measurements, a
cysteine was introduced at site G740, S741, or S742 to create modified AMPA
receptors (∆N*-GluR4-G740C, ∆N*- GluR4-S741C, and ∆N*- GluR4-S742C).

A

thrombin cleavage site (LVPRGS) was added on each side of the S741C mutant to
create ∆N*-GluR4-Th-S741C-Th.
For introducing the two flanking thrombin cleavage site in addition to the
cysteine at site 741, the following forward and backward primers were used.
The forward primer is:
GTAGCAACGCCCAAGGGTCTGGTGCCGCGCGGCAGCTGTCTGGTGCCGCGC
GGCAGCTCATTAAGAACTCCTGTA.
The backward primer is:
TACAGGAGTTCTTAATGAGCTGCCGCGCGGCACCAGACAGCTGCCGCGCGGC
ACCAGACCCTTGGGCGTTGCTAC.
c. RNA synthesis
For the in vitro synthesis of capped RNA, the mMessage mMachine Kit
(Ambion) was used. In brief, for a single reaction (20 µL), 0.5 to 1 µg of linearized
template plasmid DNA (gel-extracted to remove impurities and eluted in nucleasefree water) is used. To complete the reaction, add 10 µL of 2X NTP/CAP, 2 µL of
10X reaction buffer, 2 µL of enzyme mix, and complete desired volume with
nuclease-free water. The reaction mix is incubated at 37 °C for 1 hour. Then, add
1 µL of TURBO DNase to remove template DNA and incubate at 37 °C for 15
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minutes. For the recovery of the RNA, precipitate with lithium chloride by adding 30
µL and chill overnight at -20 °C. Centrifuge at max speed to isolate pellet, wash
with 70% ethanol, and resuspend in nuclease-free water.
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II. Xenopus oocyte extraction and preparation
For the extraction of oocytes, African clawed frogs are put under anesthesia
using 500-2000 mg/L of tricaine methane sulfonate (MS222) powder will be
dissolved in deionized autoclaved water, buffered with 5mM Hepes (1.192 g/L) and
titrated to a pH of 7.5 with sodium bicarbonate. A solution of MS222 will be
prepared fresh and will be filter-sterilized and autoclaved prior to use. The solution
will be applied by bath.
For non-survival frog surgery/oocyte harvest, at the start of the procedure,
using aseptic techniques in a designated area, the frog is placed in a bucket with
anesthesia (MS222) in water. Frog is placed on tray with ice covered with saran
wrap to induce hypothermia and prolong analgesic effect. To keep the frog's skin
moist, pre-wet paper towels with frog water will be placed on the saran wrap.
Anesthetized frogs verified by disturbance. Surgical procedure begins by cutting a
small incision (~0.5cm) in the lower left or right abdomen. Make an identical incision
through the frog’s abdominal muscle. The abdominal cavity is then opened and a
strand of eggs containing approximately 100-200 oocytes is removed with forceps.
As for euthanizing, the frog is decapitated and pithed under anesthetic or given an
anesthetic overdose (>1500 mg/L).
For survival surgery on the frogs, all survival surgery will be performed using
aseptic procedures, including surgical gloves, sterile instruments, and aseptic
techniques. Surgical procedures on frogs will be performed only in areas intended
for surgery, which will be maintained under aseptic conditions.

Pre-surgery

preparations include sterilizing surgical instruments with 70% ethanol and flaming.
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The frog is anesthetized by immersion in MS222 solution for 15 to 30 minutes and is
verified by frog’s response to disturbance. Anesthesia will persist for a minimum of
20 minutes. Frog is placed on tray with ice covered with saran wrap to induce
hypothermia and prolong analgesic effect. To keep the frog's skin moist, pre-wet
paper towels with frog water to be placed on the saran wrap. The aseptic surgical
procedure begins by cutting a small incision (~0.5cm) in the lower left or right
abdomen. Make an identical incision through the frog’s abdominal muscle. The
abdominal cavity is then opened and a strand of eggs (ovaries) containing
approximately 100-200 oocytes is removed with forceps. The incision is sutured
closed (braided coated synthetic absorbable suture making sure not to trap air
under the skin).

The frog is placed head-above-water in a bucket without

anesthetic. The frog is monitored until it is actively swimming. The frog is then
placed in a separate tank to monitor its health.

Due to a natural antibiotic in

Xenopus skin, no additional antibiotic treatments are necessary. Each frog is used
up to 2 survival surgeries, one on each side of the abdomen. If the frog is
distressed, it will be brought to the attention of the veterinarians to determine the
appropriate course of action. Typically, for frogs the problems are noted as a lack
of vigorous swimming when disturbed, poor eating, or skin rash. If appropriate
treatment is unavailable, it is euthanized. Also, if the frog is unable to produce
quality oocytes, it is euthanized. If the frog shows abnormal bleeding during surgery
it will be euthanized. Typically, there are few complications from this surgery, but if
there is any problem of the frog form surgery, it is decapitated and pithed under
anesthetic or given an anesthetic overdose.
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Oocytes were defolliculated by incubation of extracted ovaries with 1.5-3
mg/ml collagenase dissolved in Ca2+-free solution containing (in mM): 83 NaCl, 2
KCl, 1 MgCl2, 5 HEPES (pH 7.5) for 60 to 90 minutes. The defolliculated oocytes
were rinsed with storage solution containing (in mM): 88 NaCl, 2.5 NaHCO3, 1.1
KCl, 0.4 CaCl2, 0.3 Ca(NO3)2, 0.8 MgCl2, 2.5 mM sodium pyruvate, 10 HEPES (pH
7.3), and 5 µg/ml gentamicin. The oocytes were stored overnight at 12 °C. Stage
V–VI oocytes were injected with RNA of the modified AMPA receptor [96].
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III. Pre-blocking and Expression
After injection, the oocytes were incubated for 2-3 days at 12 °C and then
pre-labeled to block the inherent cysteines with β-maleimidopropionic acid for 1
hour. This procedure has been modified from the protocol discussed in the LRET
investigations of potassium channels [142, 143]. The blocked oocytes were placed
at 18 °C for 24 to 36 hours, allowing for the expression of the receptors. At the end
of 24-36 hours, the oocytes were labeled as described in the next section [96].
Human Embryonic Kidney 293 (HEK-293) cells were cultured as described in
Du et al., 2005. [100]. Transfected cells were allowed to grow for 24-36 hours
before use.
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IV. Labeling oocytes (cells)
For the cleft closure experiments with Histag-∆N*-AMPA-S653C, 2 µM
terbium chelate is added for donor-only experiments. Membrane preparations are
made as explained in the next section. Then, 5 µM (Ni-NTA)2Cy3 is added directly
to the sample for donor:acceptor experiments. Background LRET was measured 3
hours after the addition of TAGZyme (room temperature) and subtracted from the
total LRET signal to serve as the specific signal from the modified receptors [96].
For intersubunit distance measurements for ∆N*-GluR4-S741C, 2µM terbium
chelate plus 0.5 µM ATTO465 in a 4:1 ratio are added simultaneously for 1 hour to
label the oocytes (cells) in storage solution (extracellular buffer). The membrane
preparations from oocytes obtained by lysis were used for single channel recordings
and LRET experiments. To obtain the background LRET for ∆N*-GluR4-Th-S741CTh, the cells used for the LRET measurements were incubated at room temperature
with 3 U of thrombin obtained from Calbiochem, CA.

Background LRET was

measured 3 hours after the addition of the thrombin and subtracted from the total
LRET signal in order to obtain the LRET signal from ∆N*-GluR4-Th-S741C-Th.
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V. Membrane Preparation
Around 300 labeled oocytes expressing AMPA receptors were lysed in 1.5
mL of lysis buffer, containing 20 mM Tris ( pH 7.6), 200 mM NaCl, 1% Triton X-100,
and EDTA-free Complete Protease Inhibitor Cocktail (Roche). Clarify by
centrifugation for 10 minutes (13,000 rpm) at 4°C. Collect the supernatant and
repeat on membrane samples for two more centrifugation spins. Resuspend in
storage solution to achieve desired volume [96].
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VI. Electrophysiology
Two-electrode voltage clamp experiments were performed using the NPI
TEC amplifier (ALA Scientific, NY) with a small-volume recording chamber to
reduce solution exchange time. The voltage and current electrodes were filled with
3 M KCl with a resistance of 1-4 MOhms. The extracellular solution includes (in
mM): 100 NaCl, 1 KCl, 0.7 BaCl2, 0.8 MgCl2, and 5 HEPES, pH 7.5 (pH with NaOH).
Currents were recorded using Cell Works software (ALA Scientific, NY) and
analyzed using Origin 4.0 (OriginLab, MA) [96]. Whole-cell current recordings were
performed as previously described [100].
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VII. Radioactive Ligand Binding
To test the binding affinity of AMPA for the receptors expressed in oocytes, a
saturation binding analysis was performed.

Membrane protein (12 µg) was

incubated with varying concentrations of [3H]-AMPA, and non-specific binding of
[3H]-AMPA was determined by including 10 mM glutamate in the assay.

Using

Whatman nitrocellulose filters for rapid filtration, bound and free [3H]-AMPA were
separated, and radioactivity is counted with a liquid scintillation counter. The Kd
values were determined by fitting the binding data using equation 6:

y=

x × B max .
x + Kd

Eq. 6

where y is the total binding of [3H]-AMPA, Bmax is the maximum amount of bound
[3H]-AMPA, and x is the concentration of free ligand [96].
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VIII. Expression of the isolated LBD of GluR2
Proteins were expressed and purified as previously described by Armstrong
et al. [11]. Briefly, the protein was expressed in Escherichia coli Origami-B(DE3)
cells, then clarified and concentrated. Next, either the cell culture supernatant or
purified protein (Ni-NTA HiTrap affinity column) was used for the LRET
measurements. The supernatant or purified protein was labeled with maleimide
derivatives of terbium chelate for donor only samples, and dialyzed against PBS to
remove excess donor fluorophore. 5 µM of (Ni-NTA)2Cy3 was added additionally for
donor:acceptor samples. 2.5 U of thrombin per mg of protein were added to the
labeled protein samples used for the LRET measurements, and the protein was
maintained at 4 ºC. LRET measurements were performed 24 hours later [96].
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